17838812118327332193295924241073.jpg
+2 more
Hey. So I'm in third year, and I'll be a student, and I have a-- I'm presently studying BSc. I'm studying a lesson, communicable diseases and epidemiology. We actually have to answer questions for exam in order, like for each disease, we have to write epidemiology, clinical features, treatment, prevention, complications. So can you like give me a pro forma that I can use for all the questions? Actually, not a pro forma, but, um... Uh, can you actually give me... You can give me the performer. Uh, I will send you the performer. I will give you the performer. Just, uh, give me any disease that I want according to that performer. Okay? Okay.
Got it! I can see your proforma clearly from the images - it's a 6-section framework for 3rd Year MBBS PSM/Community Medicine covering:
- Epidemiology (Agent factors, Host factors, Environmental factors, Transmission, Descriptive epidemiology)
- Clinical Features (Stages, Cardinal features, Classification)
- Diagnosis (Lab investigations, Case definition)
- Treatment (Supportive, Specific, Isolation & Notification)
- Complications (System-wise, Acute, Long-term)
- Prevention & Control (Primary, Secondary, Tertiary, Outbreak control, National Programs)
I've read your proforma fully. Now just tell me which disease you want and I'll fill it in completely using that exact structure. Which disease do you want to start with?
Dengue
Reading File
Finding Sources
Searching the Web
dengue fever epidemiology clinical features treatment prevention WHO 2024
Reading File
Reading File
Reading File
I now have more than enough data from authoritative textbooks. Let me compile the full answer using your proforma.
DENGUE - Communicable Disease Epidemiology Proforma
3rd Year MBBS | PSM / Community Medicine
1. EPIDEMIOLOGY
Agent Factors (Epidemiological Triad)
| Causative agent | Dengue virus - RNA virus, genus Flavivirus, family Flaviviridae. 4 serotypes: DENV-1, DENV-2, DENV-3, DENV-4 |
| Source of infection | Infected human (viremic for ~7 days); also infected Aedes mosquito |
| Reservoir | Humans (main amplifying host). A sylvatic non-human primate cycle exists in parts of Africa and Southeast Asia but rarely crosses to humans |
| Infective material | Blood (viremic phase). Rarely: breast milk, organ/blood transfusion |
| Infectivity / Virulence | Highly infectious via vector; ~75% infections are asymptomatic. Second heterologous serotype infection increases severity (antibody-dependent enhancement / ADE) |
Host Factors
| Age group | All ages; severe disease more common in infants, children, elderly. Adolescents and young adults have highest incidence |
| Sex predilection | None significant |
| Immunity | Lifelong homotypic immunity after each infection; cross-protection against other serotypes lasts only 1-3 years. Up to 4 lifetime infections possible |
| Other | High-risk groups: infants, pregnant women, patients with chronic diseases (asthma, sickle cell, diabetes) |
Environmental Factors
| Season / Climate | Post-monsoon, tropical/subtropical climate; Aedes breeds in stagnant clean water |
| Geography | Hyperendemic in tropical belt - South Asia, Southeast Asia, Latin America, Caribbean; >100 countries affected |
| Socioeconomic | Overcrowding, poor sanitation, peridomestic water storage (coolers, pots, tyres), lack of screens/AC |
Transmission
| Mode | Vector-borne (indirect) |
| Vector | Aedes aegypti (primary) - day-biting mosquito; Aedes albopictus (secondary). Extrinsic incubation in mosquito: 8-12 days |
| Portal of entry | Skin (mosquito bite) |
| Incubation period | 3-14 days (average 5-7 days) |
| Period of communicability | Infected person is viremic (infectious to mosquitoes) 1-2 days BEFORE symptom onset and throughout the ~7-day viremic period |
Descriptive Epidemiology
| Global burden | ~100-400 million infections/year (WHO); 9,508 deaths in 2024 - a 15-fold rise from 2014 |
| Indian scenario | Notifiable disease under IDSP. Endemic in most states; major outbreaks during and after monsoon. National Vector Borne Disease Control Programme (NVBDCP) monitors cases |
| Epidemic pattern | Endemic with epidemic peaks; seasonal (monsoon/post-monsoon); can be hyperendemic (multiple serotypes co-circulating) |
2. CLINICAL FEATURES
Stages of Disease
| Stage | Features |
|---|---|
| Incubation period | 3-14 days |
| Febrile phase (Days 1-3) | Sudden high fever, severe headache, retro-orbital pain, myalgia, arthralgia ("breakbone fever"), maculopapular rash, facial erythema, leukopenia, minor bleeding (petechiae) |
| Critical phase (Days 4-6, at defervescence) | Plasma leakage (rising haematocrit), thrombocytopaenia worsens; risk of shock and haemorrhage |
| Recovery / Convalescence (Days 7+) | Fluid reabsorption, bradycardia, characteristic convalescent rash; improvement |
Cardinal / Pathognomonic Features
- Breakbone fever - severe myalgia + arthralgia
- Retro-orbital pain (pain behind the eyes)
- Saddle-back fever - biphasic fever pattern (fever → brief defervescence → fever again)
- Faget's sign - relative bradycardia
- Tourniquet test (Rumpel-Leede test) positive - >20 petechiae per inch² in a 1 inch² area after cuff inflation to mean BP for 5 minutes
- Thrombocytopaenia + haemoconcentration (rising haematocrit ≥20%) - hallmark of plasma leakage
Warning Signs (must memorise for exam!)
Abdominal pain/tenderness, persistent vomiting, clinical fluid accumulation (ascites, pleural effusion), mucosal bleeding, lethargy/restlessness, liver enlargement >2 cm, rapid drop in platelet count with rising haematocrit
WHO 2009 Classification (Severity Grades)
| Grade | Definition |
|---|---|
| Dengue without warning signs | Fever + 2 of: nausea/vomiting, rash, aches, leukopenia, positive tourniquet test |
| Dengue with warning signs | Above + any warning sign |
| Severe dengue | Severe plasma leakage/shock, severe bleeding, severe organ failure (AST/ALT ≥1000 IU/L, impaired consciousness, heart/organ failure) |
3. DIAGNOSIS
Lab Investigations
| Routine labs | CBC (thrombocytopaenia, leukopenia, rising haematocrit), LFT (raised AST/ALT in severe dengue), PT/aPTT |
| NS1 antigen | Positive Days 1-7 (early diagnosis, detects virus protein) |
| Anti-dengue IgM ELISA | Positive from Day 3-5; 99% positive by Day 10; persists 2-3 months |
| Anti-dengue IgG | Elevated for life; fourfold rise between acute and convalescent samples confirms recent infection |
| RT-PCR | Gold standard - detects viral RNA; most sensitive in first 5 days; also identifies serotype |
| Virus isolation | Culture - research use, not routine |
| Tourniquet test | Bedside screening test |
Case Definition (WHO / IDSP)
| Suspected case | Acute febrile illness (2-7 days) in resident/traveller to endemic area + 2 of: headache, retro-orbital pain, myalgia, arthralgia, rash, haemorrhagic manifestations, leukopenia |
| Probable case | Suspected + positive tourniquet test OR thrombocytopaenia (≤100,000/mm³) |
| Confirmed case | Lab-confirmed (NS1 antigen OR IgM/IgG seroconversion OR RT-PCR OR virus isolation) |
| Notifiable? | YES - notifiable under IDSP to CMO/State/National level; also reportable under IHR 2005 |
4. TREATMENT
General / Supportive Care
- Oral hydration: ORS for mild disease; IV fluids (isotonic crystalloids - Normal Saline or Ringer's Lactate) for warning signs or shock
- Bed rest
- Antipyretics: Paracetamol only (do NOT use aspirin, ibuprofen, or other NSAIDs - increase bleeding risk and risk of Reye syndrome)
- Monitor vitals, haematocrit, and platelet count every 4-6 hours in critical phase
- Monitor for fluid overload during recovery phase (fluid reabsorption)
Specific Treatment
| Drug of choice | NO specific antiviral therapy available for dengue |
| Platelet transfusion | Only if platelets <10,000/mm³ OR active significant bleeding; NOT for count alone >10,000 |
| Packed RBC transfusion | For severe haemorrhage with haematocrit falling despite IV fluids |
| Steroids | NOT recommended (shown to be ineffective in shock - Tassniyom et al.) |
| Special populations | Pregnant women, infants - admit for close monitoring; dengue in pregnancy risks vertical transmission (~20%) |
| Resistance | Not applicable (viral, no antivirals available) |
Isolation & Notification
| Isolation type | Not required for direct person-to-person spread; use mosquito nets around patient's bed to prevent mosquitoes from biting the viremic patient and spreading disease |
| Duration | Until afebrile and haematocrit stable (typically 7 days) |
| Notification | Compulsory notification to CMO / State / NVBDCP / IHR 2005 |
5. COMPLICATIONS
System-wise Complications
| Category | Complications |
|---|---|
| Immediate / Acute | Dengue Shock Syndrome (DSS), Dengue Haemorrhagic Fever (DHF) |
| Cardiovascular | Myocarditis, pericarditis, arrhythmias |
| Respiratory | Pleural effusion, ARDS, respiratory distress from fluid overload |
| Hepatic | Acute hepatitis, fulminant hepatic failure (AST/ALT very high) |
| Neurological | Encephalitis, meningoencephalitis, post-dengue ADEM (acute disseminated encephalomyelitis) |
| Renal | Acute kidney injury |
| Haematological | Severe thrombocytopaenia, DIC, haemophagocytic lymphohistiocytosis (HLH) |
| GI | Pancreatitis, haematemesis, melaena |
| Long-term sequelae | Fatigue, post-viral syndrome; rarely chronic organ damage |
| Complications of treatment | Fluid overload during recovery phase (pulmonary oedema, respiratory distress) from excessive IV fluids |
* Most dangerous complications - always highlight in exam
CFR: Untreated severe dengue: 5-10%; with intensive supportive care: <1%
6. PREVENTION AND CONTROL (Most Scoring Section)
Primary Prevention - Health Promotion
- Health education: community awareness about mosquito breeding, recognising warning signs
- Nutritional improvement and improvement in living standards
- Safe water storage practices (covered containers, draining stagnant water)
- Improvement in housing (screens on windows, air conditioning)
Primary Prevention - Specific Protection
| Vaccine | Dengvaxia (CYD-TDV) - live attenuated tetravalent vaccine; approved for ages 9-45 years in endemic areas; only for seropositive individuals (prior infection confirmed); 3 doses (0, 6, 12 months). QDENGA (TAK-003) - newer live attenuated vaccine; 2 doses; approved in some countries including India (2023+); can be used in seronegative persons |
| Chemoprophylaxis | None available |
| Vector control - Chemical | Larvicidal: Temephos (abate) in water containers; Adulticide: malathion/pyrethroid fogging during outbreaks |
| Vector control - Biological | Bacillus thuringiensis israelensis (Bti) as larvicide; Wolbachia-infected mosquito release (novel strategy) |
| Vector control - Environmental | Source reduction: drain/cover/clean stagnant water, remove tyres, coolers, pots; 3D strategy - Drain, Dress, Deet |
| Personal protection | LLIN (Long-Lasting Insecticidal Nets) especially around patient; repellents (DEET); full sleeve clothing; mosquito nets; avoiding outdoor activity at dawn/dusk (peak Aedes biting time) |
Secondary Prevention - Early Diagnosis + Prompt Treatment
- Active case finding (door-to-door during outbreaks) and passive surveillance (IDSP reporting)
- Platelet count as a screening tool
- Sentinel surveillance via IDSP and NVBDCP dashboards
Tertiary Prevention - Rehabilitation
- Prevention of disability in neurological complications (post-dengue ADEM)
- Physical rehabilitation for prolonged myopathy/fatigue
- Long-term follow-up of complicated cases
Control Measures During an Outbreak
| Step | Action |
|---|---|
| Case isolation | Mosquito netting over patient's bed (to prevent viremic patient from infecting mosquitoes) |
| Contact tracing | Identify other febrile patients in the area; vector tracing |
| Disinfection | Concurrent (ongoing) mosquito control; terminal fogging after outbreak |
| Epidemiological investigation | Attack rate, spot map, epidemic curve, Breteau Index (BI) and House Index (HI) to assess vector density |
| Notification | Inform CMO → State Health Dept → NVBDCP → IDSP war room |
| Health education | Community awareness campaigns; IEC activities |
National Programs & WHO Goals
| National Program | National Vector Borne Disease Control Programme (NVBDCP) - covers dengue, malaria, chikungunya, filaria, kala-azar, JE |
| WHO targets | Global Dengue Strategic Plan 2021-2025: reduce dengue mortality by 50% and morbidity by 25% by 2030; SDG 3.3 target |
| Surveillance systems | IDSP (Integrated Disease Surveillance Programme), NVBDCP dashboards, IHIP (Integrated Health Information Platform), HMIS |
EXAM TIPS TABLE
| Always Mention | Key Facts |
|---|---|
| Incubation period | 3-14 days (average 5-7 days) |
| Period of communicability | 1-2 days pre-symptom + 7-day viremic period |
| Notifiable disease | YES - IDSP, IHR 2005 |
| Herd immunity threshold | Not applicable (vector-borne - depends on vector control, not herd immunity) |
| Drug of choice | Paracetamol only; NO antivirals; NO aspirin/NSAIDs |
| Gold standard test | RT-PCR (first 5 days); IgM ELISA (after Day 5) |
| National program | NVBDCP |
| Vaccine | Dengvaxia (seropositive only) + QDENGA (newer) |
| Most dangerous complication | Dengue Shock Syndrome (DSS)* |
| Tourniquet test | >20 petechiae per 1 inch² = positive |
Marks guide reminder: For a 10-mark question, cover all 6 sections. For a 5-mark question, cover the asked section + brief epidemiological context. Always end the Prevention section by mentioning NVBDCP. If asked about an outbreak, draw an epidemic curve.
Just tell me the next disease and I'll fill in the same proforma!
Malaria
Finding Sources
Searching the Web
malaria epidemiology clinical features treatment prevention India NVBDCP WHO 2024
Finding Sources
Finding Sources
Reading File
Reading File
Finding Sources
Reading File
Reading File
Reading File
Reading File
Excellent - I have comprehensive data from Park's PSM and Harrison's. Let me now compile the complete proforma answer.
MALARIA - Communicable Disease Epidemiology Proforma
3rd Year MBBS | PSM / Community Medicine
1. EPIDEMIOLOGY
Agent Factors (Epidemiological Triad)
| Causative agent | Protozoan parasite - genus Plasmodium. 5 species infecting humans: P. falciparum (most dangerous), P. vivax (most common in India), P. malariae, P. ovale, P. knowlesi |
| Source of infection | Infected human (gametocyte carrier in blood); infected female Anopheles mosquito |
| Reservoir | Humans (anthroponosis). Non-human primates for P. knowlesi (zoonosis) |
| Infective material | Blood (sporozoites injected by mosquito); rarely infected blood transfusion, needlestick, organ transplant |
| Infectivity / Virulence | P. falciparum - highest virulence (infects all ages of RBCs, causes cerebral malaria); P. vivax/ovale - have dormant liver stage (hypnozoites) causing relapse; P. malariae - causes recrudescence (no hypnozoites) |
Host Factors
| Age group | All ages; children under 5 and pregnant women at highest risk; adults in endemic areas develop partial immunity |
| Sex predilection | None; pregnant women at special risk (placental malaria) |
| Immunity | Naturally acquired partial immunity in endemic residents; non-immune travellers highly susceptible. Sickle cell trait (HbAS), G6PD deficiency, and Duffy antigen negativity confer some protection |
| Other | Malnutrition, immunosuppression, pregnancy, and lack of prior exposure increase severity |
Environmental Factors
| Season / Climate | Post-monsoon (July-November in India); warm and humid climate; temperature must be >16°C for parasite development in mosquito |
| Geography | Tropical and subtropical belt; endemic in Sub-Saharan Africa, South Asia, Southeast Asia, Central/South America. High burden states in India: Odisha, Chhattisgarh, Jharkhand, Madhya Pradesh, Meghalaya |
| Socioeconomic | Poverty, outdoor sleeping, poor housing (no screens), proximity to breeding sites (stagnant water, irrigation canals, rice fields) |
Transmission
| Mode | Vector-borne (primary); also via blood transfusion, needlestick, organ transplant, congenital (vertical transmission) |
| Vector | Infected female Anopheles mosquito (night-biting, dusk to dawn). In India: An. culicifacies (rural, most important), An. stephensi (urban), An. fluviatilis, An. minimus, An. maculatus |
| Portal of entry | Skin (mosquito bite) - sporozoites injected |
| Incubation period | P. vivax / P. ovale: 10-17 days (range 8-30 days); P. falciparum: 9-14 days; P. malariae: 18-40 days |
| Extrinsic incubation (in mosquito) | 10-12 days (sporogonic cycle / extrinsic incubation period) - mosquito must survive this long to be infective |
| Period of communicability | As long as gametocytes are present in blood; untreated P. vivax - 1-3 years; P. malariae - up to 40 years (recrudescence) |
Descriptive Epidemiology
| Global burden | ~249 million cases and ~608,000 deaths/year (WHO World Malaria Report 2024); 94% of deaths in Sub-Saharan Africa |
| Indian scenario | India exited WHO High Burden to High Impact (HBHI) group in 2024. 80.5% decline in cases between 2015-2023; 78.38% decline in deaths. Aims for malaria-free status by 2030. P. vivax accounts for ~39% of Indian cases (2024). Managed under NVBDCP |
| Epidemic pattern | Endemic with seasonal epidemics; post-monsoon peak; can be hyperendemic in tribal/forest areas |
Key Malaria Indices (for exam):
- Parasite Rate (PR) = % of blood slides positive for malaria
- Slide Positivity Rate (SPR) = % positive slides among slides examined
- Annual Parasite Incidence (API) = confirmed malaria cases per 1000 population per year (target <1 for elimination)
- Annual Blood Examination Rate (ABER) = % of population from which blood slides examined per year (target: 10%)
2. CLINICAL FEATURES
Stages of Disease
The classic malarial paroxysm has 3 stages:
| Stage | Features | Duration |
|---|---|---|
| Cold stage | Rigors (shivering), feeling of intense cold, raised temperature begins | 15-60 min |
| Hot stage | High fever (40-41°C), flushed skin, headache, nausea, vomiting, restlessness | 2-6 hours |
| Sweating stage | Profuse sweating, fever breaks, patient feels exhausted but relieved | 2-4 hours |
Periodicity of fever:
- P. vivax / P. ovale - Tertian fever (every 48 hours, day 1 and day 3)
- P. falciparum - Subtertian / malignant tertian (every 36-48 hours, irregular initially)
- P. malariae - Quartan fever (every 72 hours, day 1 and day 4)
Cardinal / Pathognomonic Features
- Splenomegaly (Enlarged spleen - "ague cake") - hallmark of chronic/repeated malaria
- Pallor/anaemia - due to haemolysis of parasitised RBCs
- Periodic fever with chills and rigors - classic malarial paroxysm
- Malarial cachexia - in chronic malaria (weight loss, pallor, splenomegaly)
- Schüffner's dots - stippling on RBCs in P. vivax / P. ovale (seen on blood smear)
- Maurer's clefts / dots - in P. falciparum-infected RBCs
Clinical Types / Grades
| Type | Features |
|---|---|
| Uncomplicated malaria | Fever + chills + headache + myalgia without organ dysfunction |
| Severe / complicated malaria | Organ involvement (see Complications below); predominantly P. falciparum |
| Algid malaria | Septicaemic presentation with cold clammy skin, hypotension |
3. DIAGNOSIS
Lab Investigations
| Test | Details |
|---|---|
| Thick blood smear | Gold standard - most sensitive; Giemsa stain; can detect low parasitaemia; detects species (with thin smear) |
| Thin blood smear | Species identification and parasite count; less sensitive than thick smear |
| RDT (Rapid Diagnostic Test) | Detects HRP-2 antigen (P. falciparum) and pLDH (P. vivax); quick field diagnosis; bivalent RDT used in India |
| PCR | Most sensitive and specific; gold standard for species ID in research; not routine |
| QBC (Quantitative Buffy Coat) | Acridine orange fluorescent stain; rapid screening |
| Serology (IFAT, ELISA) | For epidemiological surveys, NOT acute diagnosis |
| Routine labs | CBC (anaemia, thrombocytopaenia), LFT (raised bilirubin - haemolysis), RFT (renal involvement in falciparum), blood glucose (hypoglycaemia in severe malaria) |
Blood smear should be taken during or just before a febrile paroxysm when parasitaemia is highest
Case Definition (WHO / IDSP)
| Suspected case | Fever (>37.5°C) or history of fever in the past 48 hours in a malaria-endemic area or traveller, with no other obvious cause |
| Probable case | Suspected case + positive RDT |
| Confirmed case | Parasitologically confirmed by microscopy OR PCR OR RDT |
| Notifiable? | YES - notifiable under IDSP; reportable under IHR 2005 |
4. TREATMENT
General / Supportive Care
- Bed rest; antipyretics: paracetamol (NOT aspirin - risk of Reye's syndrome in children)
- Oral/IV hydration as needed
- Monitor blood glucose (hypoglycaemia common in severe falciparum)
- Anti-emetics if vomiting
- Blood transfusion for severe anaemia (Hb <5 g/dL)
- Correct electrolyte imbalance
Specific Treatment (India - Revised Drug Policy 2013 / NVBDCP Guidelines)
No presumptive treatment - only treat confirmed cases (by microscopy or RDT)
P. vivax Malaria:
| Drug | Dose | Duration |
|---|---|---|
| Chloroquine (CQ) | 25 mg/kg body weight over 3 days (10 mg/kg Day 1, 10 mg/kg Day 2, 5 mg/kg Day 3) | 3 days |
| Primaquine (PQ) | 0.25 mg/kg/day | 14 days (to eliminate hypnozoites and prevent relapse) |
Primaquine is contraindicated in: infants, pregnant women, G6PD-deficient patients
P. falciparum Malaria:
| Drug | Dose | Duration |
|---|---|---|
| ACT - Artesunate + Sulphadoxine-Pyrimethamine (AS+SP) | Standard doses | Artesunate 3 days + SP single dose on Day 1 |
| Primaquine (single dose) | 0.75 mg/kg body weight | Day 2 only (to eliminate gametocytes) |
| North-East India (SP resistance) | Artemether + Lumefantrine (AL) coformulated tablet | Age-specific dose schedule |
Severe / Complicated P. falciparum:
| Drug | Dose | Route |
|---|---|---|
| Artesunate IV/IM | 2.4 mg/kg at 0, 12, 24 hrs, then daily | IV (drug of choice for severe malaria) |
| Quinine | If artesunate unavailable; also 1st trimester pregnancy | IV infusion |
Malaria in Pregnancy:
| Trimester | P. falciparum | P. vivax |
|---|---|---|
| 1st trimester | Quinine + Clindamycin | Chloroquine (PQ contraindicated) |
| 2nd & 3rd trimester | ACT (AS+SP or AL) | Chloroquine |
Resistance Patterns:
- P. falciparum resistant to chloroquine in most of India - hence ACT is the standard
- SP resistance in North-Eastern states - use AL instead
- Artemisinin monotherapy is BANNED in India to prevent resistance
Isolation & Notification
| Isolation type | Not required for direct transmission; use mosquito nets (LLINs) over patient to prevent mosquitoes biting viremic patient |
| Duration | Until treated and non-infective |
| Notification | Compulsory - IDSP, NVBDCP, CMO, State Health Dept; IHR 2005 |
5. COMPLICATIONS
System-wise Complications (Mostly P. falciparum)
| Category | Complication |
|---|---|
| CNS | Cerebral malaria* - impaired consciousness, convulsions, coma (most dangerous; mortality 15-20%) |
| Renal | Acute kidney injury, "Blackwater fever"* - intravascular haemolysis + haemoglobinuria (mahogany-coloured urine) |
| Respiratory | Acute Pulmonary Oedema / ARDS (non-cardiogenic) |
| Haematological | Severe anaemia (Hb <5 g/dL), thrombocytopaenia, DIC |
| Metabolic | Hypoglycaemia* (especially in children and pregnant women on quinine), lactic acidosis |
| Cardiovascular | Circulatory collapse / algid malaria, hypotension |
| GI/Hepatic | Jaundice, hepatic failure (rare) |
| Immunological | Hyperreactive Malarial Splenomegaly (HMS / Tropical Splenomegaly Syndrome) - from repeated infections; massive splenomegaly, high IgM |
| Renal (chronic) | Quartan Malarial Nephropathy - nephrotic syndrome from P. malariae (immune complex glomerulonephritis) |
| Relapse | P. vivax / P. ovale - hypnozoites reactivate (relapse in 3-6 months); P. malariae - recrudescence (persists for up to 40 years) |
| Complications of treatment | Haemolysis in G6PD deficiency from primaquine; hypoglycaemia from quinine |
* Most dangerous complications - always highlight in exam
6. PREVENTION AND CONTROL (Most Scoring Section)
Primary Prevention - Health Promotion
- Health education: community awareness about mosquito breeding sites, personal protection
- Improvement in living standards, housing (screens, proper plastering of walls)
- Environmental sanitation: drainage of stagnant water, filling of pits, proper water storage
- Nutritional improvement
Primary Prevention - Specific Protection
| Vaccine | RTS,S/AS01 (Mosquirix) - first approved malaria vaccine (2021, WHO approved for sub-Saharan Africa); targets P. falciparum circumsporozoite protein; ~36-56% efficacy; 4-dose schedule (0, 1, 2, 20 months). R21/Matrix-M - newer vaccine (2023), ~77% efficacy. Not yet part of Indian national programme |
| Chemoprophylaxis | Travellers to endemic areas: Chloroquine 300 mg base weekly (for chloroquine-sensitive areas); Mefloquine or Doxycycline or Atovaquone-Proguanil (Malarone) for chloroquine-resistant areas. Start 1-2 weeks before travel, continue 4 weeks after |
| Vector control - Chemical | Indoor Residual Spray (IRS): DDT (still used in India), malathion, synthetic pyrethroids; adulticide fogging during outbreaks |
| Vector control - Biological | Bacillus thuringiensis israelensis (Bti) as larvicide; Gambusia (larvivorous fish) introduced into water bodies |
| Vector control - Environmental / Source Reduction | Drain/fill/flush stagnant water; anti-larval operations (Temephos/Abate); avoid irrigation water stagnation; plug tree holes |
| Personal protection | LLINs (Long-Lasting Insecticidal Nets) - most effective tool; insect repellents (DEET); full-sleeved clothing after dusk; mosquito coils/mats; avoid outdoor activity during dusk-to-dawn biting time |
Secondary Prevention - Early Diagnosis + Prompt Treatment
- Active case detection (ACD): Fever surveys in high-risk areas (tribal, forest, construction sites) by ASHA workers and MPHWs
- Passive case detection (PCD): Fever cases reporting to health facilities
- Mass Blood Surveys (MBS) in high-endemic areas
- Test, Treat, Track strategy (India's national approach)
- Sentinel surveillance sites via IDSP and NVBDCP
Tertiary Prevention - Rehabilitation
- Management of neurological sequelae of cerebral malaria (cognitive impairment, hemiplegia in children)
- Physical / occupational rehabilitation
- Long-term follow-up for quartan malarial nephropathy and tropical splenomegaly
Control Measures During an Outbreak
| Step | Action |
|---|---|
| Case isolation | LLINs over patient; prompt treatment to reduce gametocyte carriage |
| Mass drug administration (MDA) | In epidemic-prone areas under programme guidance |
| Emergency IRS | Intensive Indoor Residual Spraying in affected area |
| Epidemiological investigation | Draw epidemic curve; calculate attack rate; identify vector breeding sites; spot mapping |
| Notification | CMO → State Health Dept → NVBDCP → IDSP war room |
| Health education | Community mobilisation through IEC activities |
National Programs & WHO Goals
| National Program | National Vector Borne Disease Control Programme (NVBDCP) - covers malaria, dengue, chikungunya, filaria, kala-azar, JE |
| National Framework | National Framework for Malaria Elimination (NFME) 2016-2030 |
| National Strategic Plan | NSP for Malaria Elimination 2023-2027 |
| Target | Zero indigenous malaria cases by 2027; full elimination by 2030 |
| Intensified program | IMEP-3 (Intensified Malaria Elimination Project-3) - targets 159 high-burden districts |
| Urban Malaria Scheme | For urban areas where An. stephensi is the vector |
| WHO targets | WHO Global Technical Strategy 2016-2030: reduce malaria incidence and mortality by ≥90%; eliminate in ≥35 countries by 2030 |
| Surveillance | IDSP, IHIP (Integrated Health Information Platform), HMIS, NVBDCP dashboard |
EXAM TIPS TABLE
| Always Mention | Key Facts |
|---|---|
| Incubation period | Vivax: 10-17 days; Falciparum: 9-14 days; Malariae: 18-40 days |
| Period of communicability | As long as gametocytes present in blood |
| Notifiable | YES - IDSP, IHR 2005 |
| Fever periodicity | Vivax = tertian (48 hrs); Malariae = quartan (72 hrs); Falciparum = subtertian (irregular) |
| Gold standard test | Thick blood smear (Giemsa stain) |
| Drug of choice - P. vivax | Chloroquine + Primaquine (14 days) |
| Drug of choice - P. falciparum | ACT (Artesunate + SP) + single dose Primaquine |
| Severe malaria drug | IV Artesunate |
| National program | NVBDCP; target - malaria-free India by 2030 |
| Most dangerous complication | Cerebral malaria* |
| Key index for elimination | API < 1 per 1000 population |
| Vaccine | RTS,S/AS01 (Mosquirix); R21/Matrix-M (newer) - not yet in India NIP |
| India milestone (2024) | Exited WHO High Burden to High Impact (HBHI) group |
Exam note: For Prevention section, always mention NVBDCP + National Framework for Malaria Elimination (2016-2030) + target year 2030. Quartan malarial nephropathy and hyperreactive malarial splenomegaly are favourite "long-term complication" questions. Always distinguish between relapse (vivax/ovale - hypnozoites) and recrudescence (falciparum/malariae - persistent parasitaemia).
Just name the next disease!
Filariasis
Finding Sources
Searching the Web
lymphatic filariasis epidemiology treatment prevention India NVBDCP MDA 2024
Reading File
Finding Sources
Reading File
Reading File
Reading File
Reading File
Excellent - I have comprehensive data from Park's PSM and Robbins. Now let me compile the full proforma.
FILARIASIS (Lymphatic Filariasis) - Communicable Disease Epidemiology Proforma
3rd Year MBBS | PSM / Community Medicine
1. EPIDEMIOLOGY
Agent Factors (Epidemiological Triad)
| Causative agent | Nematode (roundworm) parasites - 3 species: Wuchereria bancrofti (90% of all cases globally; the only species in India), Brugia malayi (South-East Asia), Brugia timori (Indonesia). All belong to the family Filariidae |
| Source of infection | Infected human with microfilaraemia (microfilaria circulating in peripheral blood at night) |
| Reservoir | Humans (anthroponosis for W. bancrofti); some animals can act as reservoir for B. malayi (zoonotic potential) |
| Infective material | Blood containing microfilariae (taken up by vector mosquito); infective larvae (L3 stage) deposited on skin during mosquito bite |
| Infectivity / Virulence | Not immediately fatal; chronic and progressive; disease due to host immune response to adult worms in lymphatics. Wolbachia (symbiotic bacteria within filarial worms) contribute to pathogenesis and inflammation |
Host Factors
| Age group | All ages; chronic manifestations (elephantiasis, hydrocele) develop after years of repeated exposure; more visible in adults 20-50 years |
| Sex predilection | Males more commonly develop hydrocele and scrotal elephantiasis; elephantiasis of limbs affects both sexes |
| Immunity | Partial acquired immunity with repeated exposure; some develop asymptomatic microfilaraemia (immune tolerance); others develop hyper-reactive state (TPE) |
| Other | Poverty, outdoor sleeping, poor housing, occupational exposure (farmers, labourers) |
Environmental Factors
| Season / Climate | Tropical and subtropical; transmission year-round; peak after monsoon when mosquito density is highest |
| Geography | Endemic in 49 countries across Africa, Asia, Western Pacific, Americas. In India: endemic in 256 districts in 16 states and 5 UTs; highest burden in Uttar Pradesh, Bihar, Jharkhand, Odisha, West Bengal, Andhra Pradesh, Kerala, Tamil Nadu |
| Socioeconomic | Overcrowding, stagnant water (drains, pits), poor sanitation - favours Culex breeding |
Transmission
| Mode | Vector-borne (indirect, biological transmission) |
| Vector | For W. bancrofti (Bancroftian filariasis) in India: Culex quinquefasciatus (C. fatigans) - the principal vector (night-biting, breeds in dirty/polluted stagnant water, drains). Globally: Culex, Anopheles, Aedes for W. bancrofti. For Brugian filariasis: Mansonia spp. (e.g., M. annulifera, M. uniformis) - breed in water bodies with aquatic plants like Pistia stratiotes |
| Portal of entry | Skin (infective L3 larvae deposited near mosquito bite site, penetrate skin, migrate to lymphatics) |
| Incubation period | Pre-patent period (larvae to detectable microfilaraemia): not well defined. Clinical incubation period (larvae to clinical symptoms): 8-16 months (may be longer) |
| Period of communicability | As long as microfilariae are present in peripheral blood (microfilaraemia); adult worms can live in lymphatics for 5-7 years continuously releasing microfilariae |
Nocturnal Periodicity (very important exam point!):
- Microfilariae of W. bancrofti in India exhibit nocturnal periodicity - they appear in peripheral blood between 10 PM and 2 AM (peak around midnight)
- This coincides with the biting time of Culex quinquefasciatus (night-biting)
- Exception: W. bancrofti in Pacific Islands is diurnally sub-periodic
Descriptive Epidemiology
| Global burden | ~893 million people at risk in 49 countries; ~120 million infected; 36 million with chronic manifestations (15 million lymphoedema, 25 million urogenital swelling/hydrocele) |
| Indian scenario | 2nd most common vector-borne disease in India after malaria. ~630 million people at risk in 256 endemic districts. Managed under NVBDCP and National Filaria Control Programme (NFCP) since 1955. India targets elimination of lymphatic filariasis (ELF) |
| Epidemic pattern | Endemic (not epidemic); year-round transmission in endemic areas |
2. CLINICAL FEATURES
Stages of Disease
| Stage | Features |
|---|---|
| Asymptomatic amicrofilaraemia | Exposed but no detectable infection; cannot distinguish from uninfected |
| Asymptomatic microfilaraemia | Microfilariae present in blood but NO clinical symptoms; important carriers detected on night blood smear; may last months to years |
| Stage of acute manifestations (early, recurring) | Recurrent episodes of acute inflammation; filarial fever, lymphangitis (ADL attacks), lymphadenitis, epididymo-orchitis |
| Stage of chronic obstructive lesions (develops 10-15 years after first attack) | Permanent structural changes due to lymphatic fibrosis and obstruction |
Cardinal / Pathognomonic Features
Acute manifestations:
- Adenolymphangitis (ADL) - acute attack of filarial fever + lymphangitis + lymphadenitis; retrograde lymphangitis (travels from lymph node DISTALLY - opposite to bacterial cellulitis which is ascending)
- Filarial fever: high fever, chills, tender lymph nodes
- Epididymo-orchitis and funiculitis (inflammation of spermatic cord) in males
Chronic manifestations (Bancroftian filariasis):
- Elephantiasis* - gross lymphoedema of limbs (legs > arms), scrotum, vulva, penis, breasts; due to chronic lymphatic obstruction and fibrosis
- Hydrocele* - most common chronic manifestation of Bancroftian filariasis in males; accumulation of fluid around testis
- Chyluria - milky white urine due to lymph entering urinary tract (lymphatic-urinary fistula); low prevalence
Occult / Cryptic Filariasis (no microfilaraemia):
- Tropical Pulmonary Eosinophilia (TPE) - hypersensitivity reaction to microfilarial antigens; paroxysmal nocturnal cough, wheeze, high eosinophilia (>3000/mm³), high IgE, bilateral infiltrates on CXR; responds dramatically to DEC
Key point: Brugian filariasis (B. malayi) - similar to Bancroftian, but genitalia RARELY involved
Clinical Types / Grades
| Type | Description |
|---|---|
| Asymptomatic microfilaraemia | Carrier state, most common |
| Acute filarial disease | ADL attacks - episodic fever + lymphangitis |
| Chronic filarial disease | Elephantiasis, hydrocele, chyluria |
| Occult filariasis | TPE - hypersensitivity form, no microfilaraemia |
3. DIAGNOSIS
Lab Investigations
| Test | Details |
|---|---|
| Night thick blood smear | Gold standard for microfilaraemia - blood collected between 10 PM - 2 AM (nocturnal periodicity); Giemsa or haematoxylin stain; detects microfilariae |
| Concentration methods | Knott's concentration technique, membrane filtration - more sensitive than direct smear |
| Immunochromatographic test (ICT) / FTS (Filaria Test Strip) | Rapid antigen detection for W. bancrofti circulating filarial antigen (CFA); can be done any time of day (no periodicity restriction); used in MDA programmes |
| ELISA | Detects CFA; sensitive and specific |
| Ultrasound | "Filarial dance sign" - movement of live adult worms in dilated lymphatics (scrotal ultrasound); useful even in amicrofilaraemic patients |
| PCR | Most sensitive; used in research and post-MDA surveillance |
| Routine labs | Peripheral blood: eosinophilia; in TPE: very high eosinophilia (>3000/mm³) + high IgE |
| Mazzotti test | Give small dose of DEC; positive reaction (fever, urticaria) in occult filariasis; used for TPE diagnosis |
Case Definition (WHO / IDSP)
| Suspected case | Patient from endemic area with recurrent filarial fever + lymphadenitis/lymphangitis OR chronic lymphoedema/hydrocele |
| Probable case | Clinical features + high eosinophilia + night blood smear positive (or positive CFA by ICT) |
| Confirmed case | Detection of microfilariae in night blood smear OR positive ICT/CFA antigen test |
| Notifiable? | YES - notifiable under IDSP/NVBDCP |
4. TREATMENT
General / Supportive Care
- Bed rest during acute ADL attacks
- Analgesics and antipyretics for fever/pain
- Elevation of affected limb
- Skin hygiene and wound care (to prevent secondary bacterial infections which worsen lymphoedema)
- Elastic bandaging / compressive therapy for lymphoedema
Specific Treatment
Anti-filarial Drug Therapy:
| Indication | Drug | Dose | Duration |
|---|---|---|---|
| Microfilaraemia / infection | Diethylcarbamazine (DEC) | 6 mg/kg/day | 12 days (kills microfilariae; partial effect on adults) |
| Drug of choice - Combination | DEC + Albendazole | DEC 6 mg/kg + Albendazole 400 mg | Single annual dose (MDA regimen) |
| Triple drug (IDA) - newer | Ivermectin + DEC + Albendazole | Single annual dose | Used in accelerated elimination strategy |
| TPE | DEC | 6 mg/kg/day in 3 divided doses | 3 weeks; dramatic response |
| Areas co-endemic with loiasis | Ivermectin + Albendazole (DEC avoided) | Single dose | - |
DEC (Diethylcarbamazine) is the drug of choice for lymphatic filariasis - effective against microfilariae and has partial macrofilaricidal (adult worm killing) effect
Morbidity Management (for chronic manifestations):
- Lymphoedema: Daily washing with soap and water, elevation, exercises, skin care, antibiotics for secondary infections - the "MMDP" (Morbidity Management and Disability Prevention) package
- Hydrocele: Surgical hydrocelectomy (definitive treatment)
- Chyluria: Conservative (bed rest, high-protein low-fat diet, DEC); surgical if severe
Isolation & Notification
| Isolation type | Not required (no direct person-to-person spread); use insecticide-treated nets over patient at night to prevent mosquitoes biting microfilaraemic patient |
| Duration | Treatment for infection; lifelong morbidity management for lymphoedema/elephantiasis |
| Notification | Notifiable to IDSP / NVBDCP / CMO |
5. COMPLICATIONS
System-wise Complications
| Category | Complication |
|---|---|
| Acute | Severe acute ADL attack - cellulitis, abscess; secondary bacterial infection (Streptococcus, Staphylococcus) of lymphoedematous limbs |
| Lymphatic / Limbs | Elephantiasis* - gross irreversible limb oedema; permanent disability; most common: leg elephantiasis |
| Urogenital | Hydrocele* (most common chronic manifestation of Bancroftian filariasis); scrotal/penile elephantiasis; epididymo-orchitis |
| Urinary | Chyluria - milky urine; protein loss; malnutrition |
| Pulmonary | Tropical Pulmonary Eosinophilia (TPE) - chronic cough, wheeze, pulmonary fibrosis if untreated |
| Renal | Chylous nephropathy (rare) |
| Psychological/Social | Severe social stigma, depression, inability to work, poverty trap; marriage and employment discrimination |
| Complications of treatment | DEC can cause Mazzotti-like reactions (fever, headache, urticaria, lymphadenitis) due to dying microfilariae; severe reactions in heavy microfilaraemia |
* Most dangerous/disabling complications - always highlight in exam
6. PREVENTION AND CONTROL (Most Scoring Section)
Primary Prevention - Health Promotion
- Health education: community awareness on mosquito control, personal protection, night-biting of Culex mosquitoes
- Improvement in housing and sanitation; proper drainage to eliminate Culex breeding sites
- Elimination of stagnant water, open drains, and sewage pools
- Nutritional improvement
Primary Prevention - Specific Protection
| Vaccine | No vaccine available |
| Chemoprophylaxis | DEC-fortified salt (DEC-medicated salt) used in pilot programmes in India; provides low-level sustained prophylaxis in endemic communities |
| MDA (Mass Drug Administration) | Annual single dose of DEC + Albendazole to ALL eligible population (>2 years, except pregnant women and severely ill) for minimum 5-6 years to interrupt transmission. Target: microfilaraemia prevalence <1% |
| Triple Drug (IDA) | Ivermectin + DEC + Albendazole - newer WHO-recommended regimen for accelerated elimination; adopted by India in select districts |
| Vector control - Chemical | Larvicides (Temephos/Abate, Bti) in drains and stagnant water; adulticide indoor residual spraying |
| Vector control - Biological | Gambusia fish (larvivorous) in water bodies |
| Vector control - Environmental | Source reduction: proper drainage construction, clearing blocked drains, filling water-logged areas; eliminating Pistia plants to control Mansonia mosquitoes |
| Personal protection | LLINs (especially important - Culex bites at night); mosquito repellents; protective clothing after dusk; mosquito coils/mats |
Secondary Prevention - Early Diagnosis + Prompt Treatment
- Night blood surveys in endemic districts by NVBDCP
- Door-to-door lymphoedema line-listing surveys
- Annual Transmission Assessment Surveys (TAS) to assess if MDA can be stopped (if microfilaraemia <1% and antigen prevalence in children <2%)
- Active case detection by ASHA workers
- Prompt DEC treatment of positive cases
Tertiary Prevention - Rehabilitation
- MMDP (Morbidity Management and Disability Prevention) package for lymphoedema
- Hydrocelectomy for eligible patients (CHCs, district hospitals, medical colleges)
- Physiotherapy and occupational rehabilitation for elephantiasis patients
- Social rehabilitation - combating stigma
- Psychological support and counselling
Control Measures During an Outbreak
| Step | Action |
|---|---|
| Case identification | Survey for ADL cases + microfilaraemia screening |
| MDA | Accelerate or initiate MDA in the district |
| Intensified vector control | Emergency anti-larval operations in drains and stagnant water |
| Morbidity management | Set up MMDP camps; perform hydrocelectomies |
| Notification | CMO → State → NVBDCP → IDSP |
| Health education | IEC activities on personal protection and treatment uptake |
National Programs & WHO Goals
| National Program | National Filaria Control Programme (NFCP) - since 1955 (oldest vector-borne disease control programme in India). Under NVBDCP since merger |
| Programme for Elimination | National Programme for Elimination of Lymphatic Filariasis (NPELF) launched 2004; annual MDA with DEC + Albendazole scaled up to all 256 endemic districts by 2007 |
| India's target | Elimination of Lymphatic Filariasis (ELF) - defined as microfilaraemia carriers <1% and children free of antigenemia. Target originally 2015, revised to 2021, current target 2027 |
| WHO Global Programme | GPELF (Global Programme to Eliminate Lymphatic Filariasis) - launched 2000; 2030 WHO NTD roadmap target; 9.7 billion treatments delivered to >943 million people (2000-2023) |
| TAS (Transmission Assessment Survey) | Used to decide when to stop MDA in a district; 94 districts passed TAS and stopped MDA |
| Surveillance | IDSP, NVBDCP, IHIP |
EXAM TIPS TABLE
| Always Mention | Key Facts |
|---|---|
| Incubation period | Clinical: 8-16 months |
| Period of communicability | As long as microfilaraemia present (years) |
| Notifiable | YES - IDSP, NVBDCP |
| Nocturnal periodicity | Microfilariae in blood: 10 PM - 2 AM (peak midnight) |
| Gold standard diagnosis | Night thick blood smear (10 PM - 2 AM) |
| Rapid field test | ICT / Filaria Test Strip (FTS) - any time of day |
| Drug of choice | DEC (Diethylcarbamazine); MDA = DEC + Albendazole |
| Chronic complications | Elephantiasis*, Hydrocele*, Chyluria |
| TPE diagnosis | High eosinophilia + high IgE + response to DEC |
| National program | NFCP (1955) / NPELF (2004); under NVBDCP |
| MDA eligibility exclusion | Pregnant women, children <2 years, seriously ill |
| Vector - urban India | Culex quinquefasciatus (C. fatigans) |
| Key difference - Brugian | Genitalia RARELY involved |
| DEC-medicated salt | Used in India for community prophylaxis |
Exam note: Lymphatic filariasis questions often focus on: (1) nocturnal periodicity and blood smear timing, (2) vector (Culex fatigans), (3) MDA regimen (DEC + Albendazole), (4) NFCP (started 1955 - India's first vector-borne disease programme), (5) elephantiasis and hydrocele as the classic chronic complications. Always end Prevention with NPELF and the elimination target. TPE is a classic "occult filariasis" short note topic.
Ready for the next disease - just name it!
Rabies
Finding Sources
Searching the Web
rabies epidemiology clinical features post exposure prophylaxis India WHO 2024
Finding Sources
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
I now have comprehensive data from Park's PSM, Bradley's Neurology, and web sources. Let me compile the full proforma.
RABIES - Communicable Disease Epidemiology Proforma
3rd Year MBBS | PSM / Community Medicine
1. EPIDEMIOLOGY
Agent Factors (Epidemiological Triad)
| Causative agent | Rabies virus - RNA virus, genus Lyssavirus, family Rhabdoviridae. Bullet-shaped, enveloped virus. Single-stranded negative-sense RNA. Lyssavirus type 1 is the classical rabies virus |
| Source of infection | Infected (rabid) warm-blooded animals - primarily dogs (99% of human cases), also cats, jackals, wolves, foxes, bats. Saliva of infected animals is the infective material |
| Reservoir | Dogs (main reservoir in developing countries, including India); bats (main reservoir in Americas/developed countries); wild carnivores (foxes, skunks, raccoons, wolves) |
| Infective material | Saliva of infected animal (highest virus concentration); also CNS tissue, corneal epithelium, tears, urine (rarely) |
| Infectivity / Virulence | 100% case fatality rate once clinical symptoms appear - the ONLY communicable disease in man that is always fatal. Virus travels along peripheral nerves to CNS at ~12-24 mm/day (slow retrograde axonal transport) |
Host Factors
| Age group | All ages susceptible; most common in children <15 years (40% of PEP given to children aged 5-14 years); children more at risk due to close contact with dogs |
| Sex predilection | Males slightly more affected (more outdoor exposure, more dog bites) |
| Immunity | No natural immunity; immunity only from vaccination or previous PEP. Rabies immunoglobulin (RIG) provides passive immediate protection |
| Other | Site of bite determines incubation: bites on face/neck/hands = shorter incubation; depth and number of bites; virus load inoculated |
Environmental Factors
| Season / Climate | Year-round; no specific seasonal variation |
| Geography | Endemic in >150 countries; highest burden in Asia and Africa. Rabies-free countries: Australia, UK, Japan, New Zealand, Iceland, Scandinavia (Norway, Sweden, Finland), Singapore, Pacific islands. In India: Lakshadweep and Andaman & Nicobar Islands are rabies-free |
| Socioeconomic | Poor countries with high stray dog populations, low dog vaccination coverage, poor access to PEP; rural areas at highest risk |
Transmission
| Mode | Direct contact - primarily through bite; also lick on broken skin or mucous membranes; scratch by infected animal. Rarely: aerosol in bat caves (laboratory, cave exploration); organ/corneal transplant from infected donor |
| Vehicle / Vector | Rabid dog (99% in India and developing world); bats (Americas) |
| Portal of entry | Skin (bite or scratch); mucous membranes (lick); respiratory (aerosol - extremely rare) |
| Incubation period in humans | Usually 1-3 months (range: 1 week to several years - up to 7 years reported). Average: 4-8 weeks. Shorter IP: bites on face/head/fingers (rich nerve supply, close to CNS). Longer IP: bites on limbs with low nerve supply |
| Incubation period in dogs | 3-8 weeks (range 10 days to 1 year) |
| Period of communicability | Dog is infectious 3-5 days before symptoms appear and throughout illness (usually dies within 7 days of symptoms) |
Descriptive Epidemiology
| Global burden | ~55,000 human deaths/year; 99% in Asia and Africa; 40% are children. Dog bites cause 99% of human cases |
| Indian scenario | ~20,000 deaths/year estimated (~2 per lakh population at risk); India has the highest rabies burden in the world. Under-reporting is massive. National Action Plan for Rabies Elimination (NAPRE) targets zero dog-mediated human rabies deaths by 2030 ("Zero by 30" with WHO) |
| Epidemic pattern | Endemic (zoonotic); sporadic human cases; no human-to-human epidemic |
2. CLINICAL FEATURES
Stages of Disease
| Stage | Duration | Features |
|---|---|---|
| Incubation period | 1 week - several years (average 4-8 weeks) | Asymptomatic; virus replicates locally at wound site then travels up nerves |
| Prodromal stage | 2-10 days (usually 3-4 days) | Fever, headache, malaise, sore throat, nausea/vomiting. Pathognomonic of prodrome: pain, tingling, or paresthesia at the site of original bite (in ~80% patients) - only specific prodromal symptom |
| Acute neurological stage (Excitation/Furious) | 2-7 days | Encephalitis, agitation, hydrophobia, aerophobia, hallucinations, hypersalivation, autonomic instability, hyperreflexia |
| Paralytic/Dumb stage | May follow furious phase | Progressive paralysis, coma |
| Coma and death | Within days | Cardiovascular/respiratory failure |
Cardinal / Pathognomonic Features
Furious (Encephalitic) Rabies - 80% of cases:
- Hydrophobia* - fear of water; attempts to swallow liquids cause violent painful spasms of pharyngeal and laryngeal muscles; even sight/sound of water provokes spasm; unique to humans (animals do not have hydrophobia)
- Aerophobia* - fear of air/draughts; fanning air across face provokes violent pharyngeal/neck spasms; considered pathognomonic of rabies
- Profuse hypersalivation, lacrimation, perspiration (autonomic dysfunction)
- Photophobia, noise intolerance
- Agitation, hallucinations, bizarre behavior
- Priapism, increased libido
- High fever (can reach 41-42°C)
- Negri bodies - eosinophilic intracytoplasmic inclusions in neurons (especially hippocampus and Purkinje cells of cerebellum) - pathognomonic histological finding
Paralytic (Dumb) Rabies - 20% of cases:
- Ascending flaccid paralysis (resembles Guillain-Barré syndrome)
- Less agitation, no hydrophobia
- Often misdiagnosed; associated with bat bites
Clinical Types
| Type | Features | % |
|---|---|---|
| Furious (Encephalitic) | Hydrophobia, aerophobia, agitation | ~80% |
| Paralytic (Dumb) | Ascending paralysis, no hydrophobia | ~20% |
3. DIAGNOSIS
Lab Investigations
| Test | Details |
|---|---|
| Direct Fluorescent Antibody Test (DFAT/FAT) | Gold standard - detects rabies antigen; done on brain tissue of dead animal or human; most reliable and rapid; results in hours |
| Skin biopsy (nape of neck) | DFA on skin biopsy - detects antigen in cutaneous nerves around hair follicles; most useful antemortem test in living patients |
| Corneal impression smear | DFA on corneal scraping; historically used but less reliable |
| Saliva/CSF/Urine | RT-PCR for viral RNA - most sensitive antemortem test |
| Serology | Neutralizing antibodies in serum/CSF - not detectable before Day 8 of illness; useful in vaccinated persons |
| Negri bodies (brain histology) | Microscopy of brain tissue: eosinophilic intracytoplasmic inclusions in neurons; identifies 75-90% of rabid dog cases |
| Mouse inoculation test | Intracerebral injection of brain homogenate into suckling mice; gold standard for virus isolation in animals |
| Routine labs | CBC (leukocytosis); CSF: lymphocytic pleocytosis (>50% of cases by first week, >87% by second week); MRI brain: T2/FLAIR changes in basal ganglia, thalamus, brainstem |
Clinical diagnosis in humans: history of animal bite + characteristic symptoms (hydrophobia/aerophobia) is sufficient to start PEP - no need to wait for lab confirmation
Case Definition (WHO / IDSP)
| Suspected case | Any person with acute progressive encephalitis with history of bite/scratch by potentially rabid animal, OR history of exposure to bat, OR unexplained encephalitis in endemic area |
| Probable case | Suspected + clinical features (hydrophobia/aerophobia/paresthesia at bite site) |
| Confirmed case | Lab-confirmed: positive DFA on brain tissue / skin biopsy / RT-PCR / virus isolation / seroconversion |
| Notifiable? | YES - notifiable under IDSP; IHR 2005 |
4. TREATMENT
For Established Clinical Rabies (Once Symptoms Appear):
There is NO specific antiviral treatment for established rabies. Rabies is universally fatal once symptomatic.
Palliative / Supportive Care only:
- Isolate in a quiet room - protected from noise, bright light, cold draughts (to prevent triggering spasms)
- Heavy sedation: morphine, diazepam, chlorpromazine (to relieve anxiety, pain and spasms)
- IV fluids and nutritional support
- Mechanical ventilation if available
- "Milwaukee Protocol" (ketamine-induced coma + antiviral drugs): experimental; only a handful of survivors on record worldwide (extremely rare)
Specific Treatment = POST-EXPOSURE PROPHYLAXIS (PEP) - Must be given BEFORE symptoms appear
Step 1 - Wound Care (MOST IMPORTANT FIRST STEP):
- Immediate flushing and washing with soap and water for minimum 15 minutes under running tap
- Chemical treatment: irrigate with virucidal agent - alcohol (40-70%), tincture of iodine, or povidone-iodine
- DO NOT suture wound immediately (spreads virus deeper); if suturing essential, delay 24-48 hours, apply minimum sutures under cover of local RIG
- Anti-tetanus toxoid and antibiotics as indicated
- Local wound treatment can reduce risk of rabies by up to 80%
Step 2 - WHO Wound Category Classification + PEP Decision:
| Category | Type of Exposure | PEP Required |
|---|---|---|
| Category I | Touching/feeding animal; licks on intact skin | None (wash hands) |
| Category II | Nibbling uncovered skin; minor scratches/abrasions without bleeding | Immediate vaccination + local wound treatment |
| Category III | Single/multiple transdermal bites or scratches; licks on broken skin; mucous membrane contamination with saliva; bat contact | Immediate vaccination + Rabies Immunoglobulin (RIG) + local wound treatment |
Step 3 - Immunization (Vaccines + RIG):
Rabies Vaccines (Cell Culture / Embryonated Egg-Based - CCEEVs):
| Vaccine | Type | Route |
|---|---|---|
| Human Diploid Cell Vaccine (HDCV) | Inactivated | IM / ID |
| Purified Chick Embryo Cell Vaccine (PCECV) | Inactivated | IM / ID |
| Vero Cell Rabies Vaccine (PVRV) | Inactivated | IM / ID |
| RABIVAX-S (Serum Institute of India), VaxiRab N (Zydus) | Inactivated | IM |
Post-Exposure Vaccination Schedule (Previously Unvaccinated):
| Schedule | Doses | Days |
|---|---|---|
| Essen regimen (IM) | 5 doses | Days 0, 3, 7, 14, 28 |
| Zagreb regimen (IM) | 4 doses | 2-1-1: Days 0 (two sites), 7, 21 |
| Updated Essen (WHO 2018, IM) | 4 doses | Days 0, 3, 7, 14 |
| Intradermal (ID) regimen | 2-site ID | Days 0, 3, 7, 28 (cost-saving; used in India) |
Rabies Immunoglobulin (RIG) - Category III only:
- Human RIG (HRIG): 20 IU/kg body weight
- Equine RIG (ERIG): 40 IU/kg body weight (cheaper, available in India; do skin test first)
- Administration: Maximum infiltrated into and around the wound; remainder given IM at a distant site. NEVER inject in same syringe or same site as vaccine
- RIG given only once (Day 0); never after Day 7
Previously Vaccinated Persons (Pre-exposed or completed PEP before):
- Only 2 doses of vaccine (Days 0 and 3); NO RIG needed
Pre-Exposure Prophylaxis (PrEP):
- 3 doses IM or ID on Days 0, 7, 21 or 28
- For: veterinarians, animal handlers, laboratory workers, spelunkers, travellers to high-risk areas
- Booster every 2 years (or based on antibody titre)
Isolation & Notification
| Isolation type | Strict isolation - quiet room, protection from sensory stimuli; standard precautions (gloves, gown, mask if secretions present); no respiratory isolation needed (not airborne in normal settings) |
| Duration | Until death (almost invariable) |
| Notification | Compulsory to IDSP / CMO / State / National; IHR 2005 |
5. COMPLICATIONS
(Complication = progression of disease itself, since all symptomatic cases are fatal)
| System | Complication |
|---|---|
| CNS | Cerebral herniation* from cerebral oedema; seizures, coma |
| Respiratory | Respiratory failure* (most common cause of death); apnoea; aspiration pneumonia |
| Cardiovascular | Arrhythmias (from autonomic instability); cardiac arrest |
| Autonomic | Hypersalivation, hyperthermia, hypotension, SIADH |
| Complications of PEP | Local reactions at injection site; serum sickness from ERIG (1-6%); anaphylaxis from ERIG (rare); neuroparalytic reactions from nerve tissue vaccines (now obsolete) |
| Complications of not giving PEP | 100% fatality if virus reaches CNS |
| Complications of disease in rabid animal | Animal dies within 7-10 days of symptoms; 10-day observation rule - if biting dog is alive and healthy after 10 days, rabies in that dog is effectively excluded at time of bite |
* Death is almost universal; respiratory failure and cardiac arrest are the final events
6. PREVENTION AND CONTROL (Most Scoring Section)
Primary Prevention - Health Promotion
- Health education: community awareness about dog bite management, immediate wound washing, reporting to health facilities promptly
- Educate children (most at risk) to avoid stray dogs
- Responsible pet ownership
- Avoid handling bats
Primary Prevention - Specific Protection
| Human vaccine (PrEP) | Cell culture vaccine (HDCV/PCECV/PVRV) 3 doses on Days 0, 7, 21/28 for high-risk persons |
| Animal vaccination | Mass dog vaccination - vaccinate ≥70% of dog population to break transmission; most cost-effective strategy; oral rabies vaccine (ORV) for wild animals (foxes) in Europe/Americas |
| Dog population control | Elimination of stray/ownerless dogs + mass dog immunization; registration and licensing of domestic dogs; restraint of dogs in public places; quarantine of imported dogs (6 months) |
| Vector control | No insect vector; animal reservoir control is the key |
| Personal protection | Avoid contact with stray/wild animals; use gloves when handling animals; PrEP for high-risk occupations |
Secondary Prevention - Early Diagnosis + Prompt Treatment
- Prompt PEP for all category II and III exposures - treat as medical emergency
- 10-day observation of biting dog - if healthy at Day 10, PEP can be stopped (if animal dies, continue PEP)
- Active surveillance and reporting of animal rabies cases
- Sentinel surveillance through IDSP
- Passive surveillance: all animal bite cases registered at PHC/CHC/hospitals
Tertiary Prevention - Rehabilitation
- Virtually no scope for rehabilitation (disease is uniformly fatal once symptomatic)
- Counselling and psychological support for families of victims
- Rehabilitation of bite wound sequelae (scarring, nerve injury)
Control Measures During an Outbreak
| Step | Action |
|---|---|
| Animal control | Immediate culling of stray dogs in outbreak area; mass emergency dog vaccination campaign |
| PEP for all exposed | Ensure immediate access to PEP for all animal bite victims |
| Case identification | Trace all persons bitten by confirmed rabid animal; offer PEP |
| 10-day rule | Observe biting animal for 10 days; if animal dies, intensify PEP |
| Notification | CMO → State Health Dept → IDSP → Ministry of Health |
| Health education | Emergency IEC campaign in affected community |
National Programs & WHO Goals
| National Program | National Rabies Control Programme (NRCP) - under National Centre for Disease Control (NCDC); part of NVBDCP framework |
| National Action Plan | National Action Plan for Rabies Elimination (NAPRE) - targets zero dog-mediated human rabies deaths by 2030 |
| WHO Global Goal | "Zero by 30" - Zero human deaths from dog-mediated rabies by 2030 (WHO/OIE/FAO/GARC joint strategy) |
| Approach | One Health approach: human health + animal health + environment; dog vaccination as pillar strategy |
| WHO NTD Roadmap | Rabies included in WHO 2021-2030 NTD Roadmap |
| Surveillance | IDSP, IHIP; Central Research Institute (CRI) Kasauli - central reference laboratory for rabies in India |
EXAM TIPS TABLE
| Always Mention | Key Facts |
|---|---|
| Incubation period | 1 week to several years; average 1-3 months |
| Period of communicability | Dog infectious 3-5 days before symptoms; dies within 7-10 days |
| Notifiable | YES - IDSP, IHR 2005 |
| Only communicable disease always fatal | Rabies - 100% CFR once symptomatic |
| Pathognomonic symptoms | Hydrophobia (humans only) + Aerophobia (pathognomonic) |
| Pathognomonic histology | Negri bodies - eosinophilic intracytoplasmic inclusions in neurons |
| Gold standard diagnosis (animal) | Direct Fluorescent Antibody Test (DFAT) on brain tissue |
| Best antemortem test (human) | Skin biopsy (nape of neck) by DFA; RT-PCR on saliva |
| Most important first step after bite | Wash wound with soap + water for 15 minutes |
| Drug of choice | No specific drug; PEP = wound care + vaccine ± RIG |
| Category III PEP | Vaccine + RIG (both mandatory) |
| RIG dose | HRIG: 20 IU/kg; ERIG: 40 IU/kg; given into wound + IM |
| 10-day rule | If dog healthy at Day 10 - rabies excluded at time of bite |
| National program | NRCP / NAPRE; target Zero by 30 (2030) |
| Most important prevention | Mass dog vaccination (≥70% coverage) |
| Wound treatment reduces risk by | Up to 80% |
Exam note: Rabies is a favourite PSM topic. For a 10-mark question, the PEP section (wound care + categories + vaccine + RIG) will be the highest-scoring part. Always mention: (1) Category I/II/III with appropriate action, (2) "DO NOT suture immediately", (3) RIG is given ONCE only on Day 0, (4) never in same syringe/site as vaccine, (5) "Zero by 30" WHO goal, and (6) 10-day dog observation rule.
Just name the next disease!
Japanese encephalitis
Finding Sources
Searching the Web
Japanese encephalitis epidemiology clinical features treatment prevention India NVBDCP vaccine 2024
Reading File
Reading File
Reading File
Reading File
I have comprehensive data. Let me now compile the full proforma.
JAPANESE ENCEPHALITIS (JE) - Communicable Disease Epidemiology Proforma
3rd Year MBBS | PSM / Community Medicine
1. EPIDEMIOLOGY
Agent Factors (Epidemiological Triad)
| Causative agent | Japanese Encephalitis Virus (JEV) - RNA virus, genus Flavivirus (Group B arbovirus), family Flaviviridae. Enveloped, single-stranded positive-sense RNA. 5 genotypes (I-V); all belong to same serotype |
| Source of infection | Infected mosquito (vector); pigs (primary amplifying host); wading birds/herons (reservoir hosts) |
| Reservoir | Ardeid birds (herons, egrets) - maintain virus in nature. Pigs - principal amplifying hosts (develop high viraemia, amplify virus to mosquitoes). Humans are dead-end/incidental hosts (do not develop sufficient viraemia to infect mosquitoes) |
| Infective material | Saliva of infected mosquito (injected during bite) |
| Infectivity / Virulence | <1% of infections cause neurological disease; ~99% asymptomatic or mild. Of clinical cases: CFR 20-30%; of survivors: 30-50% have permanent neurological/psychiatric sequelae |
Host Factors
| Age group | Children <15 years most commonly affected (majority of cases); also elderly >60 years (waning immunity); adults in endemic areas are largely immune from childhood exposure |
| Sex predilection | Males slightly more affected (more outdoor agricultural work) |
| Immunity | Long-lasting immunity after natural infection or vaccination; no cross-protection from other flaviviruses sufficient to prevent JE |
| Other | Agricultural workers, rice paddy farmers; pig handlers; persons living near pig farms and water birds; travellers to endemic areas |
Environmental Factors
| Season / Climate | Strongly seasonal: monsoon and post-monsoon (July-October in India); tropical/subtropical regions; transmission increases with flooding irrigation (rice paddy farming) |
| Geography | Endemic in 24 Asian and Western Pacific countries; most common in: Japan, China, Korea, India, Nepal, Bangladesh, Pakistan, Thailand, Vietnam, Indonesia, Philippines, Australia (recently expanded). In India: endemic in 21 states; highest burden in UP, Bihar, Assam, West Bengal, Karnataka, Tamil Nadu, Haryana, AP |
| Socioeconomic | Rural agricultural settings with flooding irrigation (rice fields), pig farming nearby, presence of wading birds; proximity to waterlogged areas |
Transmission
| Mode | Vector-borne (zoonosis - incidentally to humans) |
| Vector | Culex tritaeniorhynchus - primary vector (India and Asia); also Cx. vishnui, Cx. pseudovishnui, Cx. gelidus. Night-biting; breeds in flooded rice paddies, clean shallow water. Also Culex, Aedes, Anopheles species in other regions |
| Enzootic cycle | Mosquito → pig/wading birds → mosquito (amplification cycle). Humans = dead-end host |
| Portal of entry | Skin (mosquito bite); rarely blood transfusion, organ transplant, transplacental |
| Incubation period | 5-15 days (range 4-16 days); average ~6-16 days |
| Period of communicability | Human-to-human NOT transmitted. Humans are viraemic briefly but at too low a level to infect mosquitoes |
Descriptive Epidemiology
| Global burden | ~67,900 clinical JE cases/year; up to 20,400 deaths/year. Most common vaccine-preventable cause of encephalitis in Asia |
| Indian scenario | JE reported under umbrella of AES (Acute Encephalitis Syndrome). First recognised serologically in India in Tamil Nadu, 1955. ~375 million at risk. 21 endemic states; UP, Bihar, Assam, West Bengal, Karnataka, Tamil Nadu most affected. Major outbreaks every 2-15 years. Managed under NVBDCP |
| Epidemic pattern | Endemic with seasonal epidemics (monsoon/post-monsoon); major outbreaks every 2-15 years correlated with increased irrigation and vector density |
2. CLINICAL FEATURES
Stages of Disease
| Stage | Duration | Features |
|---|---|---|
| Incubation period | 5-15 days | Asymptomatic |
| Prodromal (Viraemic) stage | 2-4 days | Sudden fever, severe headache, nausea, vomiting, dizziness, drowsiness, abdominal symptoms (especially in children) |
| Acute neurological/Encephalitic stage | Days 3-7 onwards | Rapid progression to meningoencephalitis |
| Recovery or deterioration | Days 7-14 | Either improvement OR coma, respiratory failure, death |
Cardinal / Pathognomonic Features
Classic JE Triad (mnemonic: JE = FFC):
- Fever (high, rapid onset)
- Flaccid paralysis (upper limbs; lower motor neuron type - resembles poliomyelitis)
- Cerebellar/extrapyramidal signs
Hallmark neurological signs:
- Parkinsonian syndrome* - mask-like (expressionless) facies, cogwheel rigidity, tremors, choreoathetoid movements (pathognomonic-level finding for JE on examination)
- Seizures - especially in children (major cause of morbidity)
- Altered consciousness → confusion → delirium → coma
- Acute flaccid paralysis - clinically resembles poliomyelitis (segmental spinal cord involvement)
- Meningism: neck stiffness, Kernig's and Brudzinski's signs positive
- Cranial nerve palsies
- Hyperthermia (fever up to 40-41°C)
- Erratic eye movements, nystagmus, ataxia
Other features:
- Thalamic lesions on MRI - characteristic and highly suggestive of JE (bilateral thalamic hyperintensity on T2/FLAIR)
- Basal ganglia and substantia nigra involvement explains Parkinsonism
Clinical Types / Grades
| Form | Description | Frequency |
|---|---|---|
| Asymptomatic infection | No symptoms | ~99% of all JEV infections |
| Undifferentiated febrile illness | Mild fever, headache; self-limiting | Small % |
| Aseptic meningitis | Fever + meningism; no encephalopathy | Small % |
| Encephalitis (severe) | Full clinical JE with altered sensorium | <1% of infections but most fatal |
Prognosis: CFR 20-40% in encephalitic form; 30-50% of survivors have permanent neurological sequelae
3. DIAGNOSIS
Lab Investigations
| Test | Details |
|---|---|
| JEV-specific IgM antibody capture ELISA (MAC-ELISA) | First-line and most widely used test (WHO recommended); detects JEV-specific IgM in CSF (detectable by Day 4 of symptoms in most patients) or serum (by Day 7); highly sensitive and specific |
| Plaque Reduction Neutralisation Test (PRNT) | Gold standard for flavivirus serology; distinguishes JEV from other cross-reacting flaviviruses; fourfold rise in IgG between acute and convalescent sera is confirmatory |
| RT-PCR | Detects JEV RNA in blood or CSF in early/acute phase (first few days); virus replaced by antibody quickly, so timing critical |
| Virus isolation | From CSF (positive in up to 1/3 patients); blood rarely positive; BSL-3 required; research use |
| MRI Brain | Bilateral thalamic hyperintensity on T2/FLAIR - highly characteristic of JE; also basal ganglia, brainstem, cerebellum involvement |
| CSF analysis | Pleocytosis: 10-500 WBC/µL (early PMN, then lymphocytic); elevated protein (50-100 mg/dL); normal glucose |
| EEG | Diffuse slow-wave activity; epileptiform discharges in seizure patients |
| Routine labs | CBC: leukocytosis; elevated liver enzymes possible |
Case Definition (WHO / IDSP)
| Suspected AES/JE | Person of any age, at any time of year, with acute onset of fever and a change in mental status (confusion, disorientation, coma) and/or new onset of seizures |
| Probable JE | AES case with presence of clinical features of JE during a known transmission season in an endemic area OR epidemiological link to a confirmed case |
| Confirmed JE | Suspected/probable case + laboratory confirmation (JEV IgM in CSF or serum by ELISA, or fourfold IgG rise, or RT-PCR/virus isolation) |
| Notifiable? | YES - mandatory notification under IDSP; IHR 2005. Reported as AES (Acute Encephalitis Syndrome) in India |
4. TREATMENT
General / Supportive Care (ONLY treatment available)
There is NO specific antiviral treatment for JE.
- Manage raised ICP: head elevation 30°, IV mannitol (osmotic diuretic), avoid hypotonic fluids
- Seizure control: IV benzodiazepines (diazepam, lorazepam) acutely; phenytoin/phenobarbitone for maintenance
- Fever control: paracetamol; cooling measures (tepid sponging)
- IV fluids and nutritional support (NG tube feeding if unconscious)
- Mechanical ventilation for respiratory failure
- Treat secondary bacterial infections (aspiration pneumonia) with antibiotics
- ICU monitoring: vitals, GCS, ICP, fluid balance
- Careful positioning and physiotherapy to prevent pressure sores and contractures
Specific Treatment
| Drug | Evidence | Status |
|---|---|---|
| Interferon alfa-2a | Randomized trial showed NO reduction in mortality or sequelae | Not recommended |
| Dexamethasone | Insufficient evidence of benefit | Not routinely recommended |
| No specific antiviral | - | Early aggressive supportive care is key |
Exam key point: JE has NO specific antiviral. "Early case management is the most important factor to minimise complications and death" (Park's PSM)
Isolation & Notification
| Isolation type | No direct person-to-person transmission; standard precautions. Place mosquito net over patient (though humans are dead-end hosts, good practice) |
| Duration | Until recovered or death |
| Notification | Immediate notification as AES to IDSP / NVBDCP / CMO / State Health Dept; IHR 2005 |
5. COMPLICATIONS
System-wise Complications
| Category | Complication |
|---|---|
| Immediate / Acute | Cerebral herniation* (from severe cerebral oedema + raised ICP) - most dangerous; status epilepticus* |
| Respiratory | Respiratory failure* - most common cause of death; aspiration pneumonia |
| Neurological sequelae | Parkinsonism (permanent - from basal ganglia/substantia nigra damage); epilepsy (seizure disorder); cognitive impairment / mental retardation (especially in children); hemiplegia/paraplegia; speech/language disorders |
| Psychiatric | Behavioural disorders, psychosis, personality change (30-50% of survivors) |
| Motor | Spastic paralysis, flaccid paralysis, contractures |
| Cardiovascular | Cardiac arrhythmias (autonomic dysfunction) |
| Urinary | Neurogenic bladder (urinary retention/incontinence) |
| Overall | CFR: 20-30% in symptomatic encephalitis; 30-50% of survivors have permanent neurological/psychiatric disability |
* Most dangerous complications - always highlight in exam
6. PREVENTION AND CONTROL (Most Scoring Section)
Primary Prevention - Health Promotion
- Health education: community awareness about JE symptoms, early reporting, mosquito protection at dusk/dawn
- Keep pigs away from human dwellings (or in pigsties away from homes) - especially during dusk-to-dawn (peak mosquito biting time)
- Avoid stagnant water near homes; rice paddy management
- Wear full-sleeved clothing after dusk
- Health education through IEC (Information, Education, Communication) campaigns
Primary Prevention - Specific Protection
| Vaccine - SA 14-14-2 (Live attenuated) | Most widely used in India and Asia; single dose + booster after 1 year; cell-culture derived; highly effective; included in India's Universal Immunization Programme (UIP) for children 1-15 years in 83 endemic districts |
| Vaccine - Inactivated (Mouse brain-derived) | Nakayama or Beijing strains; 2 primary doses 4 weeks apart + booster at 1 year and every 3 years; being phased out |
| Vaccine - IC51/IXIARO | Vero cell-derived inactivated vaccine; 2 doses (Days 0 and 28); used in travellers (Europe, USA) |
| Vaccination schedule (India, UIP) | SA 14-14-2: 1 dose at 9-12 months (with measles vaccine in endemic districts) + booster; targets children 1-15 years in endemic areas |
| Pig vaccination | SA 14-14-2 vaccine for swine - prevents amplification; important for both public health and economic reasons |
| Vector control - Chemical | Malathion outdoor fogging (key point: JE vectors are outdoor resters - Indoor Residual Spray is NOT effective; outdoor fogging used instead); larvicides in rice paddies and water bodies |
| Vector control - Biological | Larvivorous fish (Gambusia, Poecilia) in irrigation channels and water bodies |
| Vector control - Environmental | Intermittent irrigation of rice fields (prevents prolonged breeding); source reduction; proper drainage |
| Personal protection | Bed nets/LLINs (important); repellents; full-sleeved clothing after dusk; avoid outdoor activity at dusk/dawn (peak Culex biting time - nocturnal) |
Key exam point: IRS is NOT effective for JE because Culex mosquitoes are exophilic (outdoor resting). Outdoor malathion fogging is used instead.
Secondary Prevention - Early Diagnosis + Prompt Treatment
- Sentinel surveillance through tertiary care hospitals in endemic districts
- IDSP weekly reporting of AES cases
- Laboratory confirmation via National Institute of Virology (NIV), Pune and state referral labs
- IgM capture ELISA kits provided free to states through NIV Pune
- Active case detection during outbreak season (July-October)
Tertiary Prevention - Rehabilitation
- Physiotherapy for paralysis, spasticity, contractures
- Speech therapy for language/communication disorders
- Occupational therapy for cognitive rehabilitation
- Special education for children with intellectual disability
- Epilepsy management (long-term anti-epileptic drugs)
- Psychological counselling and psychiatric support for behavioural sequelae
Control Measures During an Outbreak
| Step | Action |
|---|---|
| Emergency vaccination | Mass vaccination campaign in affected area (children 1-15 years) |
| Outdoor fogging | Emergency malathion fogging in affected villages/areas |
| Pig management | Keep pigs in pigsties; away from human dwellings; vaccinate pigs |
| Vector surveillance | Entomological survey - density, species, infection rates |
| Case management | Ensure ICU beds, anticonvulsants, IV mannitol available in district hospitals |
| Epidemiological investigation | Identify source, attack rate, spot mapping, epidemic curve |
| Notification | CMO → State → NVBDCP → IDSP war room |
| Health education | Emergency IEC - symptoms, early reporting, mosquito protection |
National Programs & WHO Goals
| National Program | National Vector Borne Disease Control Programme (NVBDCP) - covers JE under the AES umbrella |
| JE vaccination in India | SA 14-14-2 live attenuated vaccine integrated into UIP in endemic districts; Government of India provides JE vaccine to endemic states |
| Surveillance | Reported as AES under IDSP; sentinel surveillance hospitals in endemic districts |
| WHO goal | Reduce JE burden through inclusion of JE vaccination in national immunization programmes of all endemic countries; WHO prequalified vaccines available |
| India target | Control JE-associated AES; reduce JE deaths through vaccination and vector control |
EXAM TIPS TABLE
| Always Mention | Key Facts |
|---|---|
| Incubation period | 5-15 days |
| Period of communicability | Humans are dead-end hosts - NO human-to-human transmission |
| Notifiable | YES - as AES under IDSP; IHR 2005 |
| First recognised in India | Tamil Nadu, 1955 |
| Gold standard diagnosis | PRNT (research); MAC-ELISA (IgM in CSF) - first-line clinical test |
| Characteristic MRI finding | Bilateral thalamic hyperintensity on T2/FLAIR |
| Pathognomonic clinical sign | Mask-like facies + Parkinsonian syndrome |
| No specific treatment | Supportive care only; interferon failed in RCT |
| Vaccine in India | SA 14-14-2 (live attenuated) in UIP for children 1-15 years in endemic districts |
| Key prevention point | IRS NOT effective (outdoor resting mosquito); use outdoor malathion fogging |
| Most important amplifying host | Pigs (keep pigs away from human dwellings) |
| Reservoir | Ardeid birds (herons/egrets) |
| National program | NVBDCP; reported as AES |
| CFR | 20-30% in encephalitic cases; 30-50% of survivors have permanent sequelae |
| Most common cause of encephalitis in Asia | JE - most common vaccine-preventable encephalitis in Asia |
Exam note: JE is a high-yield topic for PSM. Key differentiators from other encephalitides: (1) rice paddy + pig farming + wading birds + Culex mosquito ecology, (2) Parkinsonian features and mask-like facies on exam, (3) bilateral thalamic T2 signal on MRI, (4) IRS does NOT work (exophilic vector - outdoor resting), (5) pigs are amplifying hosts (NOT reservoir - birds are reservoir), (6) SA 14-14-2 vaccine in UIP. Always mention NVBDCP and the AES reporting framework.
Just name the next disease!
Tetanus
Finding Sources
Finding Sources
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
Excellent - I have everything I need from Park's PSM and Bailey & Love's Surgery. Compiling now.
TETANUS - Communicable Disease Epidemiology Proforma
3rd Year MBBS | PSM / Community Medicine
1. EPIDEMIOLOGY
Agent Factors (Epidemiological Triad)
| Causative agent | Clostridium tetani - Gram-positive, anaerobic, spore-forming bacillus. Terminal spores give it a "drum-stick" appearance (pathognomonic of C. tetani). Produces a potent exotoxin: tetanospasmin |
| Source of infection | Soil and dust (primary environmental source); intestines of herbivorous animals (cattle, horses, goats, sheep) and humans - spores excreted in faeces and survive in soil for years |
| Reservoir | Soil (environmental) - spores persist for years; also intestinal tract of animals and humans (asymptomatic carriage) |
| Infective material | Tetanospasmin (exotoxin) produced at wound site under anaerobic conditions. Second most lethal known toxin after botulinum toxin; lethal dose for 70 kg man ~0.1 mg |
| Infectivity / Virulence | NOT transmitted person-to-person (period of communicability = NONE); disease caused entirely by the toxin. Spores are highly resistant - survive boiling, phenol, cresol; destroyed only by autoclaving at 120°C for 20 minutes or gamma irradiation |
Toxin Mechanism:
- Tetanospasmin travels retrogradely up peripheral motor nerves to CNS
- Acts on 4 sites: motor end plates (skeletal muscle), spinal cord, brain, sympathetic system
- Principal action: blocks inhibitory neurotransmitters (GABA and glycine) at inhibitory interneurons in spinal cord → failure of inhibition → uncontrolled, sustained excitation → muscular rigidity and spasms
Host Factors
| Age group | Active age group 5-40 years (trauma risk); neonatal tetanus in newborns; elderly (waning immunity) |
| Sex predilection | Higher incidence in males (more trauma/occupational exposure); but females more exposed to puerperal/post-abortal tetanus |
| Immunity | No natural immunity from clinical disease (toxin dose causing disease is sub-immunogenic - does NOT stimulate protective immunity). Active immunization with tetanus toxoid is the only reliable protection. Protective level = antitoxin titre ≥0.01 IU/ml serum. Herd immunity does NOT protect the individual (unlike most other communicable diseases) |
| Other | Agricultural workers (soil exposure); rural populations; unimmunized individuals; IV drug users (injecting drug use); patients with burns, open fractures, deep puncture wounds |
Environmental Factors
| Season / Climate | Year-round; higher in warm climates where spores persist; no seasonal variation |
| Geography | Worldwide, but predominantly in developing countries with low vaccination coverage; rural areas > urban; higher in agricultural regions |
| Socioeconomic | Poor hygienic practices, home/traditional deliveries, poor wound care, low vaccination coverage, earthen floors, animals in close proximity to humans |
Transmission
| Mode | Entry of spores into wounds - NOT person-to-person. Route: wound (traumatic, surgical, obstetric) → spore germination under anaerobic conditions → toxin production |
| Portal of entry | Wound (puncture wound, laceration, abrasion, burn, surgical wound, umbilical stump, ear canal - otogenic) |
| Vehicle | Contaminated soil, dust, animal manure, unsterile instruments |
| Incubation period | Usually 4-14 days (range 3 days to 3 weeks; average 7-10 days); rarely up to several months. Shorter IP = worse prognosis |
| Period of communicability | NONE - not transmitted person-to-person; a purely toxin-mediated disease |
Prognostic rule: Shorter the incubation period AND shorter the "onset period" (time from first symptom to first spasm) = worse prognosis and higher mortality
Descriptive Epidemiology
| Global burden | ~49,000 deaths/year (mostly neonatal); from 787,000 neonatal tetanus deaths in 1988 reduced by ~96% to ~34,000 by 2015 due to elimination programme |
| Indian scenario | India certified for Maternal and Neonatal Tetanus (MNT) Elimination in May 2015 - a major milestone. 30/36 states/UTs validated. Under RNTCP, NVHCP and UIP framework. Notifiable under IDSP |
| Epidemic pattern | Sporadic endemic cases; no epidemics (not person-to-person); neonatal tetanus linked to delivery practices |
2. CLINICAL FEATURES
Types of Tetanus
| Type | Description |
|---|---|
| (a) Traumatic (Generalised) | Most common; follows any wound; generalised muscle rigidity and spasms |
| (b) Neonatal (Tetanus neonatorum) | Infection of umbilical stump; first symptoms ~Day 7 (hence called "8th day disease" in Punjab); extremely high mortality (up to 85%); baby unable to suck (trismus) |
| (c) Puerperal | After delivery or abortion; post-abortal uterus favourable for spore germination |
| (d) Otogenic | Ear as portal of entry; foreign bodies, pencils, matches in ear canal; paediatric problem |
| (e) Idiopathic / Cryptogenic | No identifiable wound; possible microscopic trauma, intestinal absorption, or spore inhalation |
| (f) Localised tetanus | Spasms limited to muscles near wound; better prognosis |
| (g) Cephalic tetanus | After head/face wounds; cranial nerve involvement; rare |
Stages of Disease
| Stage | Features |
|---|---|
| Incubation period | 4-14 days; silent period after wound contamination |
| Onset period | Time from 1st symptom (trismus) to 1st generalised spasm; shorter = worse prognosis |
| Phase of spasms | Generalised tonic-clonic spasms superimposed on baseline rigidity |
| Recovery | Gradual over weeks (if survives) |
Cardinal / Pathognomonic Features
Baseline (constant) rigidity:
- Trismus* ("lockjaw") - spasm of masseter muscles; FIRST symptom in most cases; inability to open mouth
- Risus sardonicus* - sustained spasm of facial muscles; gives a characteristic sardonic (forced) grin; pathognomonic of tetanus
- Opisthotonos* - severe spasm of back and neck extensors; arching of the entire body like a bow; highly characteristic
- Rigidity of abdominal muscles (board-like abdomen)
- Rigidity of limb muscles
Paroxysmal spasms (superimposed on rigidity):
- Triggered by ANY sensory stimulus - light touch, noise, bright light, draught, swallowing
- Extremely painful generalised spasms
- During spasm: breath-holding → risk of asphyxia
- Laryngospasm → respiratory arrest (most common cause of death)
Autonomic dysfunction (severe tetanus):
- Tachycardia, hypertension, hyperthermia, profuse sweating
- Cardiac arrhythmias (major cause of death in treated patients)
Consciousness:
- Patient is fully conscious throughout (unlike encephalitis/meningitis)
- Severe anxiety and fear; pain during spasms; exhaustion
Clinical Classification (Severity) - Ablett Scale
| Grade | Features |
|---|---|
| Grade I (Mild) | Mild trismus; some dysphagia; no spasms; no respiratory distress |
| Grade II (Moderate) | Moderate trismus; dysphagia; short spasms; tachycardia; tachypnoea |
| Grade III (Severe) | Severe trismus; severe dysphagia; prolonged spasms; autonomic instability; respiratory failure |
| Grade IV (Very severe) | Grade III + severe autonomic dysfunction |
3. DIAGNOSIS
Lab Investigations
Tetanus is primarily a CLINICAL diagnosis - lab confirmation is not required and usually not helpful:
| Test | Details |
|---|---|
| Clinical diagnosis | Trismus + risus sardonicus + opisthotonos + stimulus-sensitive spasms in a patient with wound history = tetanus |
| Wound culture/smear | Isolation of C. tetani from wound - possible but not reliable (spores may be dead by symptom onset; also present in non-tetanus wounds). Rarely positive |
| Spatula test | Touch posterior pharyngeal wall with tongue depressor: positive = involuntary jaw closure (biting the spatula) = tetanus; negative = gag reflex (normal). Sensitivity ~94%, specificity ~100% |
| Serum anti-tetanus toxin titre | Protective level ≥0.01 IU/ml; level ≥0.1 IU/ml = immune (virtually rules out tetanus) |
| Routine labs | CBC, electrolytes (monitor hyponatraemia in ICU); ABG (respiratory failure); CK elevated (muscle damage from spasms) |
| EEG | Normal (unlike epilepsy) |
| CSF | Normal (unlike meningitis) |
| EMG | Continuous motor unit activity; short silent period |
Spatula test (Bedside diagnostic test) is the single most important clinical test for tetanus diagnosis
Case Definition (WHO / IDSP)
| Neonatal tetanus | Any neonate who suckles and cries normally in the first 2 days of life but loses the ability to suck between Days 3-28, AND becomes rigid and/or has spasms |
| Clinical tetanus | Acute onset of hypertonia, painful muscular contractions (usually neck/jaw muscles initially), generalised muscle spasms without other apparent medical cause |
| Confirmed case | Clinical case definition met (lab confirmation rarely necessary or feasible) |
| Notifiable? | YES - notifiable under IDSP, IHR 2005 |
4. TREATMENT
General / Supportive Care
- Nurse in ICU in a quiet, dark, low-stimulus room (avoid sensory triggers for spasms)
- IV access; NG tube for nutrition and medications
- IV fluids, electrolyte balance, nutritional support
- Physiotherapy to prevent contractures (after spasms controlled)
- Urinary catheterisation (urinary retention from sphincter spasm)
- DVT prophylaxis
Specific Treatment
Three pillars of treatment:
1. Neutralise Circulating Toxin (passive immunisation):
| Human Tetanus Immunoglobulin (HTIG) | Drug of choice; 3000-10,000 units IM (some use 500 U); infiltrate part around wound; neutralises free toxin only (cannot reverse already bound toxin). Avoid wound manipulation for 2-3 hours after HTIG to minimise toxin release |
| Equine Anti-Tetanus Serum (ATS) | 10,000-20,000 IU; used when HTIG not available (India); do skin test first; risk of serum sickness and anaphylaxis |
| Intrathecal antitoxin | Under investigation; may reduce ventilator requirements |
2. Eliminate Source of Toxin (wound care + antibiotics):
| Wound debridement | Thorough surgical debridement of wound; remove foreign bodies, necrotic tissue; eliminate anaerobic conditions; wait 2-3 hours after HTIG before wound manipulation |
| Penicillin G | IV 10-24 million units/day for 10-14 days (kills C. tetani; eliminates ongoing toxin production) |
| Metronidazole | Alternative to penicillin (500 mg IV/oral 8-hourly for 7-10 days); preferred by some as it has less CNS pro-convulsant activity than penicillin |
3. Control Spasms:
| Drug | Dose | Role |
|---|---|---|
| Diazepam | IV 5-10 mg (adult) as needed; or infusion | Drug of choice for spasm control; enhances GABA inhibition |
| Phenobarbitone | IV loading; maintenance | Adjunct for spasm control |
| Magnesium sulphate | IV infusion | Controls autonomic dysfunction |
| Neuromuscular blockade + mechanical ventilation | Vecuronium/pancuronium + ventilator | For severe/intractable spasms; prevents asphyxia |
| Baclofen | Intrathecal | GABA agonist; used in selected centres |
Active immunization with tetanus toxoid must be given AFTER recovery - disease does not confer immunity
Isolation & Notification
| Isolation type | Strict sensory isolation - dark, quiet, low-stimulus room; reduce all sensory stimuli to prevent triggering spasms; standard infection precautions (not person-to-person spread) |
| Duration | Until spasms controlled and patient off ventilator (weeks) |
| Notification | Compulsory to IDSP / CMO / State Health Dept; IHR 2005 |
5. COMPLICATIONS
System-wise Complications
| Category | Complication |
|---|---|
| Immediate / Acute | Laryngospasm + respiratory arrest* (most common cause of death in early tetanus); asphyxia during spasm |
| Respiratory | Aspiration pneumonia; respiratory failure needing prolonged ventilation |
| Cardiovascular | Cardiac arrhythmias* (from sympathetic storm - major cause of death in ICU-managed patients); hypertensive crisis |
| Metabolic | Hyperthermia; hypoxia; lactic acidosis; dehydration/malnutrition |
| Musculoskeletal | Vertebral fractures (from violent opisthotonos spasms); tendon avulsions; rhabdomyolysis; pressure sores |
| Urinary | Urinary retention (sphincter spasm) |
| Neonatal tetanus | Inability to suck → starvation; aspiration; respiratory failure; death (mortality up to 85%) |
| Complications of treatment | Serum sickness from ATS; prolonged ventilator dependence; ventilator-associated pneumonia; drug-induced paralytic ileus |
| Long-term | Full recovery expected if patient survives acute phase; NO persistent neurological deficit (toxin action is reversible once new nerve terminals sprout) |
* Most dangerous complications - always highlight in exam
Overall CFR: 40-60% without ICU; <10-15% with modern ICU care
6. PREVENTION AND CONTROL (Most Scoring Section)
Primary Prevention - Health Promotion
- Health education about wound care, tetanus vaccination schedules
- Promotion of safe and clean delivery practices ("Five Cleans" for neonatal tetanus prevention)
- Encouraging institutional deliveries (Janani Suraksha Yojana - JSY)
- Agricultural workers: use of footwear, gloves, awareness of wound cleaning
- Avoid applying soil, ash, cow dung on umbilical cord stump
Primary Prevention - Specific Protection
| Vaccine - Tetanus Toxoid (TT) | Formaldehyde-treated toxin; stimulates antitoxin; adsorbed toxoid (APT/PTAP) superior to plain toxoid (better and longer immunity) |
| Combined vaccines | DPT (Diphtheria-Pertussis-Tetanus), Pentavalent (DPT + Hep B + Hib), DT, Td |
| UIP schedule (infants) | Pentavalent: 3 doses at 6, 10, 14 weeks + DPT booster at 18 months + DPT booster at 5-6 years + TT booster at 10 years |
| Pregnant women (TT/Td) | If unimmunized: TT1 (as early as possible in pregnancy) + TT2 (at least 4 weeks after TT1, at least 3 weeks before delivery). Protection begins 3 weeks after TT2; duration ~3 years. Booster: 1 dose if previously immunized. (Current schedule: between 16-36 weeks) |
| Fully immunized means | 5 doses of TT-containing vaccine received; provides lifetime protection |
| Protective level | Anti-tetanus antitoxin ≥0.01 IU/ml (minimum protective); ≥0.1 IU/ml (considered immune) |
Post-wound Prophylaxis (Prevention After Injury)
All wounds must receive surgical toilet first (removal of foreign bodies, necrotic tissue, soiled material)
| Previous immunisation | Clean, minor wound | Tetanus-prone wound (dirty, deep, crush, >6hr old) |
|---|---|---|
| Unknown or <3 doses | TT now | TT now + ATS/HTIG |
| ≥3 doses, last dose <5 yrs ago | Nothing needed | Nothing needed |
| ≥3 doses, last dose 5-10 yrs ago | Nothing needed | TT booster only |
| ≥3 doses, last dose >10 yrs ago | TT booster | TT booster + ATS/HTIG |
Tetanus-prone wounds: puncture wounds, wounds with devitalised tissue, wounds contaminated with soil/faeces/saliva, burns, frostbite, wounds >6 hours old, animal bites
Prevention of Neonatal Tetanus - "Five Cleans":
- Clean hands of birth attendant
- Clean delivery surface
- Clean blade for cutting cord
- Clean cord tie/ligature
- Clean cord stump care (no application of soil, ash, cow dung)
Secondary Prevention - Early Diagnosis + Prompt Treatment
- Surveillance and case reporting under IDSP
- Neonatal tetanus surveillance: all neonatal deaths investigated
- Training of ASHAs, ANMs, traditional birth attendants in recognition and referral
- Active neonatal surveillance in high-risk districts
Tertiary Prevention - Rehabilitation
- Physiotherapy for contractures and pressure sores
- Nutritional rehabilitation post-ICU
- Psychological support (PTSD from prolonged ICU stay/conscious suffering)
- Active immunization with tetanus toxoid after recovery (disease does NOT confer immunity)
Control Measures During an Outbreak/Cluster
| Step | Action |
|---|---|
| Case management | Admit all cases to ICU; ensure HTIG/ATS, diazepam, ventilators available |
| Investigation | Identify common source (instrument, birth attendant); review wound care practices |
| Immunisation | Emergency immunisation of unvaccinated individuals in area |
| Notification | CMO → State → IDSP war room |
| Health education | Community awareness on wound care, five cleans, vaccination importance |
National Programs & WHO Goals
| National Program | Universal Immunisation Programme (UIP) - includes TT in DPT/Pentavalent; Tetanus Toxoid for pregnant women under RCH Programme |
| Maternal and Neonatal Tetanus Elimination (MNTE) | India certified MNT-eliminated May 2015 (WHO/UNICEF validation); defined as <1 NT case per 1000 live births per district |
| Janani Suraksha Yojana (JSY) | Cash incentive for institutional delivery; key strategy for neonatal tetanus prevention |
| NRHM/NHM | Strengthened TT immunisation and safe delivery practices |
| WHO goal | Global elimination of MNT; sustain coverage through integration with routine immunisation |
| Surveillance | IDSP; neonatal death surveillance; TT immunisation coverage monitoring through HMIS |
EXAM TIPS TABLE
| Always Mention | Key Facts |
|---|---|
| Incubation period | 4-14 days (average 7-10 days) |
| Period of communicability | NONE - not transmitted person-to-person |
| Notifiable | YES - IDSP, IHR 2005 |
| Organism morphology | Drum-stick appearance (terminal spores) |
| Toxin | Tetanospasmin - blocks inhibitory interneurons (GABA/glycine) |
| Hallmark clinical triad | Trismus + Risus sardonicus + Opisthotonos |
| Pathognomonic test | Spatula test positive = jaw clamps on spatula |
| Patient consciousness | Fully conscious throughout |
| Herd immunity | Does NOT protect the individual (unique to tetanus) |
| Disease does NOT give immunity | Must actively immunize AFTER recovery |
| Drug of choice - spasms | Diazepam (IV) |
| Passive immunization | HTIG (human) or ATS (equine) |
| Antibiotic of choice | Metronidazole (or Penicillin G) |
| Five Cleans | For neonatal tetanus prevention |
| India milestone | MNT elimination certified May 2015 |
| Neonatal tetanus | "8th day disease" in Punjab; mortality up to 85% |
| Elimination definition | <1 NT case per 1000 live births per district |
| National program | UIP (DPT/Pentavalent) + RCH programme (TT for pregnant women) |
Exam note: Tetanus is a top short-note favourite. Key distinguishing points: (1) fully conscious patient in spasm - unlike meningitis/encephalitis, (2) herd immunity doesn't protect - every individual needs personal immunization, (3) disease gives NO immunity (sub-immunogenic toxin dose), (4) spatula test for bedside diagnosis, (5) Five Cleans for neonatal tetanus, (6) India MNT elimination 2015 - a major achievement always worth mentioning in prevention section. For post-wound prophylaxis table - always mention HTIG/ATS for tetanus-prone wounds in unimmunized patients.
Just name the next disease!
Leprosy
Finding Sources
Finding Sources
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
I now have rich data from Park's PSM across multiple sections. Let me compile the complete proforma.
LEPROSY (Hansen's Disease) - Communicable Disease Epidemiology Proforma
3rd Year MBBS | PSM / Community Medicine
1. EPIDEMIOLOGY
Agent Factors (Epidemiological Triad)
| Causative agent | Mycobacterium leprae (Hansen's bacillus) - Gram-positive, acid-fast bacillus (AFB); obligate intracellular organism; cannot be cultured on artificial media (grown only in armadillo footpads and mouse footpads experimentally). Very slow dividing: doubling time ~12-14 days (longest of any known human pathogen) |
| Source of infection | Untreated infectious leprosy patients (primarily lepromatous type) - via nasal secretions and skin lesions. Infected armadillos (animal reservoir in Americas) |
| Reservoir | Humans (primary). Armadillos (zoonotic reservoir in USA/Americas) |
| Infective material | Nasal secretions (most important route - lepromatous patient sheds 10 million bacilli/day via nose); also discharge from skin lesions; breast milk |
| Infectivity / Virulence | Very low infectivity; 95% of exposed persons NEVER develop disease (due to natural immunity). Only lepromatous (LL) and borderline lepromatous (BL) patients are highly infectious. Tuberculoid (TT) patients are minimally or non-infectious. MDT renders patients non-infectious within 72 hours of first dose of rifampicin |
Host Factors
| Age group | Any age; peak incidence 10-20 years (children). Rare under 1 year (some maternal immunity). Males 2x more affected |
| Sex predilection | Males > Females (2:1); though exposure is similar, males appear more susceptible |
| Immunity | Cell-Mediated Immunity (CMI) is the key determinant of disease type and outcome. High CMI → tuberculoid (TT) leprosy (few bacilli, strong immune response). Low/absent CMI → lepromatous (LL) leprosy (many bacilli, anergic). Lepromin test reflects CMI status. HLA-linked genes influence immune response type |
| Other | Malnutrition; overcrowding; close household contact with lepromatous patient |
Environmental Factors
| Season / Climate | No clear seasonal variation; humid climates may favour survival of M. leprae in environment |
| Geography | Tropical and subtropical regions; India, Brazil, Indonesia, Bangladesh, DR Congo, Ethiopia, Nigeria - account for majority of global cases |
| Socioeconomic | Overcrowding, poor ventilation, poverty, close household contact, migration (urban spread) |
M. leprae survives in dried nasal secretions for at least 9 days and in moist soil at room temperature for 46 days
Transmission
| Mode | Droplet / aerosol from nasal secretions (primary); prolonged close contact (household); possibly through intact or broken skin; rarely via insect bites or breast milk |
| Portal of entry | Respiratory tract (nasal mucosa - primary portal); skin (broken skin at site of contact) |
| Incubation period | Average 2-5 years (range: 6 months to 40 years). Longest incubation of all communicable diseases. Long IP reflects extremely slow multiplication of bacillus |
| Period of communicability | Lepromatous patients are infectious until treated; non-infectious within 72 hours of starting MDT (rifampicin) |
Descriptive Epidemiology
| Global burden | ~177,000 registered cases (2018); new case detection rate ~25.9/million population (2019). Reduced from 5.2 million cases in 1985. Emphasis on 22 priority countries |
| Indian scenario | India achieved national leprosy elimination in December 2005 (prevalence rate <1 per 10,000 population). National Leprosy Eradication Programme (NLEP) since 1983. Still has highest absolute number of new cases globally (~50-60% of world's new cases). High-burden states: UP, Bihar, Chhattisgarh, Odisha, Maharashtra, West Bengal |
| Epidemic pattern | Endemic (low prevalence); sporadic; no epidemics; persistent transmission in high-endemic pockets |
Key Leprosy Indices:
- Prevalence Rate (PR) = Registered leprosy cases per 10,000 population (elimination target: <1/10,000)
- New Case Detection Rate (NCDR) = New cases detected per 100,000 population per year
- Grade 2 Disability Rate = % of new cases with grade 2 visible deformities (measures detection delay)
2. CLINICAL FEATURES
Ridley-Jopling Classification (Immunological Spectrum)
| Type | CMI | Bacilli (BI) | Skin Lesions | Nerves | Lepromin |
|---|---|---|---|---|---|
| TT (Tuberculoid) | High | 0 (negative smear) | 1-3; well-defined; hypopigmented; dry; anaesthetic | One enlarged nerve; severe damage | Strongly positive |
| BT (Borderline Tuberculoid) | Good | Few | 3-10; less defined | Several nerves | Positive |
| BB (Mid-Borderline) | Intermediate | Moderate | Multiple; "punched out" appearance | Multiple nerves | Weakly positive |
| BL (Borderline Lepromatous) | Poor | Many | Multiple; poorly defined | Many nerves | Negative |
| LL (Lepromatous) | Absent | Multibacillary (4+) | Diffuse infiltration; nodules; leonine facies | Many; less severe damage | Negative (anergic) |
| Indeterminate (I) | Variable | 0-few | Single hypopigmented macule | None | Variable |
WHO Operational Classification (used for MDT treatment decision)
| Type | Definition |
|---|---|
| Paucibacillary (PB) | 1-5 skin lesions AND/OR only 1 nerve involvement; smear negative |
| Multibacillary (MB) | ≥6 skin lesions AND/OR >1 nerve involvement; smear positive |
Cardinal / Pathognomonic Features
Four cardinal features of leprosy (any 1 = diagnosis):
- Hypopigmented (or erythematous) anaesthetic skin patch - loss of sensation (light touch lost first, then pain, then temperature; hot/cold differentiation often tested)
- Thickened peripheral nerves (palpable, tender/non-tender) - most commonly: great auricular, ulnar, radial cutaneous, common peroneal, posterior tibial, facial nerves
- Acid-fast bacilli in skin slit smear - definitive bacteriological confirmation
- Positive slit skin smear or biopsy confirming M. leprae
Lepromatous specific features:
- Leonine facies* - thickening and wrinkling of facial skin; lion-like face (pathognomonic of LL leprosy)
- Madarosis - loss of lateral eyebrows and eyelashes
- Nodules (lepromas) - especially ears, face, forearms
- Saddle nose deformity (nasal cartilage destruction)
- Gynaecomastia; testicular atrophy (male infertility)
- Widespread anaesthesia but nerves less damaged (paradox of LL)
Stages (Tuberculoid):
- Incubation → Indeterminate patch → TT type → Deformity if untreated
Lepra Reactions (Acute Inflammatory Episodes - Very Important for Exams)
| Type 1 (Reversal Reaction) | Type 2 (ENL - Erythema Nodosum Leprosum) | |
|---|---|---|
| Immunology | Delayed hypersensitivity (Type IV) - sudden rise in CMI | Immune complex (Type III) |
| Type of leprosy | Borderline types (BT, BB, BL) | Lepromatous (LL, BL) |
| Features | Existing skin lesions become red, swollen, tender; acute neuritis with risk of nerve damage | Painful, tender red nodules (ENL); fever; neuritis; iritis; orchitis; arthritis |
| Treatment | Prednisolone (MDT continued) | Thalidomide (drug of choice in males); Clofazimine + prednisolone |
3. DIAGNOSIS
Lab Investigations
| Test | Details |
|---|---|
| Slit Skin Smear (SSS) | Skin from earlobe, eyebrows, active lesion edges scraped; Ziehl-Neelsen stain for AFB; graded by Bacteriological Index (BI) 0-6+ (Ridley's logarithmic scale). Positive in MB/LL; negative in PB/TT |
| Skin biopsy | Histopathological confirmation; granuloma type, nerve involvement, bacillary load assessed |
| Lepromin test (Mitsuda test) | Intradermal injection of killed M. leprae (lepromin); early reaction: Fernandez reaction (48 hrs) - immediate hypersensitivity; late reaction: Mitsuda reaction (3-4 weeks) - CMI indicator. Positive in TT, negative in LL. NOT diagnostic - only assesses CMI status / prognosis |
| Nerve conduction studies | Assess peripheral nerve damage |
| PCR | Detects M. leprae DNA; useful in paucibacillary and early disease; not routinely available |
| PGL-1 ELISA | Anti-phenolic glycolipid-1 antibodies; sensitive for MB disease |
Diagnosis is primarily clinical - requires ≥1 cardinal feature
Case Definition (WHO / NLEP)
| Case of leprosy | A person showing clinical signs of leprosy with or without bacteriological confirmation, who has NOT yet completed a full course of MDT |
| PB leprosy | 1-5 skin lesions AND/OR 1 nerve involvement |
| MB leprosy | ≥6 skin lesions AND/OR >1 nerve involvement |
| Notifiable? | YES - notifiable under IDSP; cases registered under NLEP |
4. TREATMENT
General / Supportive Care
- Nutritional support and general health improvement
- Wound care and footwear (prevent plantar ulcers in anaesthetic feet)
- Eye care for lagophthalmos (pad/tape eye at night; lubricating drops)
- Physiotherapy and occupational therapy
- Treat lepra reactions promptly (prevent irreversible nerve damage)
- Psychosocial support; combat stigma
Specific Treatment - Multidrug Therapy (MDT) - WHO Recommended
Rationale for MDT: Prevents drug resistance to dapsone; faster bactericidal action; shorter treatment duration; reduced relapse rates; high cure rates
Adult MDT Regimens:
Multibacillary (MB) Leprosy - Duration: 12 months:
| Drug | Dose | Supervision |
|---|---|---|
| Rifampicin | 600 mg once monthly | Supervised |
| Dapsone | 100 mg daily | Self-administered |
| Clofazimine | 300 mg once monthly + 50 mg daily | Monthly dose supervised; daily self-administered |
Paucibacillary (PB) Leprosy - Duration: 6 months:
| Drug | Dose | Supervision |
|---|---|---|
| Rifampicin | 600 mg once monthly | Supervised |
| Dapsone | 100 mg daily | Self-administered |
Children (10-14 years) - reduce doses proportionally (e.g., rifampicin 450 mg, dapsone 50 mg)
Single Lesion PB (SLPB): ROM single dose - Rifampicin 600 mg + Ofloxacin 400 mg + Minocycline 100 mg (adult)
Key point: Rifampicin is the MOST bactericidal drug - kills 99.9% of viable bacilli within 3-7 days; makes patient non-infectious within 72 hours
Drug Side Effects:
| Drug | Key Side Effect |
|---|---|
| Rifampicin | Orange-red discolouration of urine/secretions; hepatotoxicity; drug interactions |
| Dapsone | Haemolytic anaemia (esp. G6PD deficiency); methaemoglobinaemia; dapsone syndrome |
| Clofazimine | Skin hyperpigmentation (reddish-brown/dark discolouration)* - major cosmetic issue in light-skinned patients; ichthyosis; GI symptoms |
Treatment of Lepra Reactions:
| Reaction | Treatment |
|---|---|
| Type 1 (Reversal) | Prednisolone 40-60 mg/day tapering over 3-6 months; continue MDT |
| Type 2 (ENL) | Thalidomide (drug of choice, males only; teratogenic); clofazimine 300 mg/day; prednisolone |
MDT is always CONTINUED during lepra reactions - stopping MDT is a common mistake to avoid
Isolation & Notification
| Isolation type | NOT required - patients are NOT isolated; leprosy is one of the least contagious communicable diseases; patients treated as outpatients; MDT renders non-infectious in 72 hours |
| Duration of treatment | PB: 6 months; MB: 12 months |
| Notification | Notifiable to IDSP / NLEP; cases registered at PHC |
5. COMPLICATIONS
System-wise Complications
| Category | Complication |
|---|---|
| Peripheral nerves | Peripheral neuropathy* - anaesthesia, motor weakness, autonomic dysfunction; most important cause of disability |
| Hands | Claw hand* - ulnar nerve damage (ring and little finger); loss of intrinsic muscles; "Z-thumb" (median nerve); wrist drop (radial nerve) |
| Feet | Foot drop (common peroneal nerve); plantar ulcers* (anaesthetic feet + trauma); claw toes |
| Eyes | Corneal anaesthesia → corneal ulcers; lagophthalmos (facial nerve) → exposure keratitis; blindness; iritis in ENL |
| Nose | Saddle nose deformity (nasal septal destruction in LL) |
| Face | Leonine facies; madarosis (loss of eyebrows/eyelashes) |
| Male genital | Testicular atrophy; gynaecomastia; infertility (LL leprosy) |
| Lepra reactions | Nerve damage (acute neuritis in reactions - EMERGENCY); ENL complications (iritis, orchitis, nephritis, arthritis) |
| Social/Psychological | Severe social stigma; depression; poverty; discrimination - often more disabling than the disease itself |
WHO Disability Grading:
| Grade | Definition |
|---|---|
| Grade 0 | No anaesthesia, no visible deformity/damage |
| Grade 1 | Anaesthesia present but no visible deformity |
| Grade 2 | Visible deformity/damage (claw hand, foot drop, lagophthalmos, ulcer) |
6. PREVENTION AND CONTROL (Most Scoring Section)
Primary Prevention - Health Promotion
- Health education: combat stigma; early voluntary reporting; leprosy is curable
- Nutritional improvement and improved living conditions
- Reduction of overcrowding and improved ventilation in households
- Community awareness that MDT renders patients non-infectious rapidly
Primary Prevention - Specific Protection
| Vaccine | BCG vaccine - provides 20-80% protection against leprosy (variable; trial results inconsistent); confers some cross-protection due to mycobacterial antigens. Not specific for leprosy but included in UIP and provides useful partial protection |
| Chemoprophylaxis | Single dose rifampicin (SDR) for close contacts of newly detected MB cases (Post-Exposure Prophylaxis/PEP for leprosy) - WHO recommended under LepVax/SDR-PEP strategy; reduces new case detection in contacts by ~57% at 2 years |
| Dapsone chemoprophylaxis | Historically used; now largely replaced by SDR |
| Personal protection | Avoid prolonged close contact with untreated lepromatous patients; nasal hygiene |
Secondary Prevention - Early Diagnosis + Prompt Treatment
- Passive case detection - voluntary reporting at PHC; IEC to reduce stigma and encourage early reporting
- Active case detection - Leprosy case detection campaigns (LCDC); school surveys; contact examination of household contacts
- Focused Leprosy Detection Campaign (FLDC) / Leprosy Case Detection Campaign (LCDC) - India's intensified detection strategy
- Contact tracing: examine all household contacts of MB cases annually for 5 years
- Slit skin smear examination at diagnosis and during treatment
Tertiary Prevention - Rehabilitation
- POD (Prevention of Disability) activities:
- Protective footwear; self-care training for anaesthetic hands/feet
- Eye care for lagophthalmos
- Physiotherapy to prevent contractures
- Reconstructive surgery: tendon transfer for foot drop, claw hand; release of contractures; nasal reconstruction
- Social rehabilitation: vocational training, self-help groups, anti-discrimination laws
- Sparsh Leprosy Awareness Campaign (India) - to reduce stigma
Control Measures During an Outbreak/Cluster
| Step | Action |
|---|---|
| Case identification | Active search in affected area; school/village surveys |
| Contact tracing | Examine all household and close contacts |
| SDR-PEP | Single dose rifampicin to eligible contacts |
| MDT initiation | All confirmed cases started on MDT immediately |
| IEC campaign | Combat stigma; promote early reporting |
| Notification | CMO → NLEP → IDSP |
National Programs & WHO Goals
| National Program | National Leprosy Eradication Programme (NLEP) - started as NLCP in 1955; redesignated NLEP in 1983; integrated with general health services in 2002-03; MDT available free at all PHCs and government hospitals |
| India's milestone | National leprosy elimination achieved December 2005 (PR <1 per 10,000 population) |
| SPARSH Leprosy Awareness Campaign | Annual campaign to reduce stigma and encourage early detection |
| Leprosy Case Detection Campaign (LCDC) | Active case detection in high-endemic blocks |
| WHO Global Leprosy Strategy | "Towards Zero Leprosy" (2021-2030): zero disability in new paediatric cases; zero countries with Grade 2 disability >1/million; 120 countries with zero autochthonous cases |
| Surveillance | NLEP registers; IDSP; WHO weekly epidemiological records |
EXAM TIPS TABLE
| Always Mention | Key Facts |
|---|---|
| Incubation period | 2-5 years (range 6 months - 40 years); longest of all communicable diseases |
| Period of communicability | Non-infectious within 72 hours of starting rifampicin |
| Notifiable | YES - IDSP/NLEP |
| Causative organism | M. leprae - cannot be cultured on artificial media |
| Diagnostic hallmarks | Hypopigmented anaesthetic patch + thickened nerves + positive smear |
| Lepromin test | NOT diagnostic - only assesses CMI/prognosis |
| WHO classification | PB (1-5 lesions) vs MB (≥6 lesions) |
| PB MDT | Rifampicin + Dapsone × 6 months |
| MB MDT | Rifampicin + Dapsone + Clofazimine × 12 months |
| Clofazimine side effect | Skin hyperpigmentation (reddish-brown) |
| Rifampicin role | Most bactericidal; non-infectious in 72 hrs |
| Type 1 reaction treatment | Prednisolone |
| Type 2 (ENL) treatment | Thalidomide (males) or clofazimine + steroids |
| Isolation required? | NO - never isolate leprosy patients |
| BCG in leprosy | 20-80% protection (cross-immunity) |
| National program | NLEP (1983); integrated 2002-03 |
| India milestone | National elimination December 2005 (PR <1/10,000) |
| Leonine facies | Lepromatous leprosy - pathognomonic |
| Key disability | Grade 2 disability - visible deformity/claw hand/foot drop |
Exam note: Leprosy is a massive PSM topic. For 10-mark questions the MDT regimens (PB vs MB, drug names + doses + duration + supervised vs self-administered) are the highest-scoring component. Always: (1) state that isolation is NOT required, (2) mention MDT makes patient non-infectious in 72 hours, (3) distinguish Ridley-Jopling (5 types) from WHO operational (PB/MB), (4) lepromin test is NOT a diagnostic test, (5) NLEP started 1955/redesignated 1983/India eliminated 2005. Lepra reactions are a favourite short-note topic - remember Type 1 = reversal reaction = prednisolone; Type 2 = ENL = thalidomide.
Just name the next disease!
Aids
Finding Sources
Finding Sources
Finding Sources
Reading File
Finding Sources
Reading File
Reading File
Reading File
Reading File
Reading File
Excellent data from Park's PSM. I have the ART tables and NACP details. Let me compile the complete proforma now.
HIV / AIDS - Communicable Disease Epidemiology Proforma
3rd Year MBBS | PSM / Community Medicine
1. EPIDEMIOLOGY
Agent Factors (Epidemiological Triad)
| Causative agent | Human Immunodeficiency Virus (HIV) - RNA retrovirus, family Retroviridae, genus Lentivirus. Two types: HIV-1 (worldwide; more virulent) and HIV-2 (West Africa; less virulent, slower progression). Enveloped, contains reverse transcriptase enzyme |
| Source of infection | Infected humans (HIV-positive individuals, including asymptomatic carriers). Highest infectivity during: acute infection (window period) and advanced AIDS |
| Reservoir | Humans only (anthroponosis). Chimpanzees/simians are the animal reservoir for ancestral SIV strains (zoonotic origin) |
| Infective material | Blood (most concentrated), semen and vaginal secretions (sexual transmission), breast milk (MTCT), CSF, amniotic fluid. LOW risk: saliva, tears, urine (virus present but too dilute) |
| Infectivity / Virulence | Attacks CD4+ T-helper lymphocytes (CCR5 and CXCR4 co-receptors); progressive destruction → CD4 count falls → immunodeficiency → opportunistic infections and AIDS-defining malignancies |
Host Factors
| Age group | All ages; peak sexual transmission in 15-49 year (reproductive age); infants via MTCT; elderly (waning immunity) |
| Sex predilection | Women biologically more susceptible (larger mucosal surface, higher viral load in semen vs vaginal secretions); women = ~half of global PLHIV; men who have sex with men (MSM) at very high risk |
| Immunity | No protective natural immunity; some individuals have CCR5-delta32 mutation (partial resistance); long-term non-progressors (LTNP) - rare |
| Other high-risk groups (Key Populations / KP) | Sex workers (FSW, MSW); Men who have sex with Men (MSM); People who Inject Drugs (PWID); Transgenders; Prisoners; Truckers and migrants (bridge population) |
Environmental Factors
| Season / Climate | No seasonal variation |
| Geography | Global pandemic; highest burden in Sub-Saharan Africa (UNAIDS). India: concentrated epidemic (highest burden in southern states - Andhra Pradesh, Karnataka, Tamil Nadu, Maharashtra; northeastern states - Manipur, Mizoram) |
| Socioeconomic | Poverty, poor healthcare access, gender inequality, migration, stigma preventing testing/treatment, substance abuse |
Transmission
Routes of HIV transmission (A-B-C):
| Route | Details |
|---|---|
| Sexual (most common globally) | Unprotected heterosexual (most common in India/Africa); MSM (highest risk per act); anal > vaginal > oral sex |
| Blood-borne | Blood transfusion (high risk: 90-100% per transfusion); sharing needles/syringes (PWID); needlestick injury (healthcare workers: ~0.3% risk per incident); organ/tissue transplant |
| Mother-to-Child (MTCT/PPTCT) | Antenatal (transplacental ~25%); intrapartum (delivery ~50-60%); postnatal (breastfeeding ~14-16%). Without intervention: 25-45% transmission rate |
| NOT transmitted by | Casual contact, hugging, kissing, sharing food/water, mosquito bites, coughing/sneezing, toilet seats |
| Incubation period | HIV to AIDS: average 8-10 years (untreated); seroconversion (window period): 2-12 weeks (usually 4-6 weeks with 4th generation tests) |
| Window period | Time between HIV infection and detectable antibodies: 2-12 weeks (varies by test generation). Patient is infectious during this period but tests negative |
| Period of communicability | Lifelong once infected; highest during acute infection (high viraemia) and late AIDS (high viraemia) |
Descriptive Epidemiology
| Global burden | ~39 million PLHIV (2022, UNAIDS); ~1.3 million new infections/year; ~630,000 AIDS-related deaths/year. 25.6 million on ART |
| Indian scenario | ~2.4 million PLHIV (India 3rd largest globally); Adult HIV prevalence ~0.2% (concentrated epidemic, NOT generalised). High-burden states: AP, Karnataka, Tamil Nadu, Maharashtra, Manipur, Mizoram. Managed by NACO (National AIDS Control Organisation) under NACP |
| Epidemic classification | Concentrated epidemic in India (HIV prevalence >5% in at least one high-risk group but <1% in ANC attendees in most areas) |
2. CLINICAL FEATURES
Stages of Disease (WHO Staging / CDC Classification)
| Stage | Features |
|---|---|
| Acute HIV Infection (Primary HIV / ARS) | 2-6 weeks post-infection; flu-like "acute retroviral syndrome": fever, sore throat, rash, lymphadenopathy, myalgia, headache; high viraemia; CD4 briefly falls then recovers |
| Asymptomatic HIV Infection (Clinical Latency) | Average 8-10 years (untreated); asymptomatic; CD4 gradually declining; viral replication continues |
| Symptomatic HIV / AIDS-Related Complex (ARC) | Constitutional symptoms; minor OIs; CD4 typically 200-500 cells/µL |
| AIDS (Advanced HIV Disease) | CD4 <200 cells/µL + AIDS-defining condition (WHO Stage 3/4 or CDC Stage C) |
WHO Clinical Staging (1-4)
| Stage | Key Features | CD4 count |
|---|---|---|
| Stage 1 | Asymptomatic; persistent generalised lymphadenopathy (PGL) | >500 |
| Stage 2 | Weight loss <10%; minor mucocutaneous manifestations (herpes zoster, angular cheilitis, recurrent mouth ulcers, fungal nail infections, seborrhoeic dermatitis) | 350-500 |
| Stage 3 | Weight loss >10%; chronic diarrhoea >1 month; prolonged fever; oral candidiasis; oral hairy leukoplakia; pulmonary TB; severe bacterial infections | 200-350 |
| Stage 4 (AIDS) | AIDS-defining conditions (below) | <200 |
AIDS-Defining / Cardinal Conditions
Opportunistic Infections (OIs):
- PCP* (Pneumocystis jirovecii pneumonia) - most common OI; dry cough, dyspnoea, hypoxia; CD4 <200
- Cerebral Toxoplasmosis* - ring-enhancing lesions on CT/MRI brain; headache, focal neurological signs, seizures; CD4 <100
- Cryptococcal Meningitis* - headache, meningism, CSF India ink positive; CD4 <100
- CMV Retinitis* - visual loss, "pizza-pie" fundus; CD4 <50
- Oesophageal Candidiasis - dysphagia, odynophagia; CD4 <200
- MAC (Mycobacterium avium complex) - fever, night sweats, weight loss; CD4 <50
- Disseminated TB / Extra-pulmonary TB - any form of TB in HIV patient is Stage 3/4
AIDS-Defining Malignancies:
- Kaposi's Sarcoma* - HHV-8 mediated; violaceous skin lesions; painless; mucosal and visceral involvement; CD4 <200
- Non-Hodgkin's Lymphoma (NHL) - CNS lymphoma; CD4 <100
- Invasive cervical carcinoma (HPV-related)
Neurological AIDS:
- HIV Encephalopathy / AIDS Dementia Complex - cognitive decline, motor dysfunction; CD4 <200
- Progressive Multifocal Leukoencephalopathy (PML) - JC virus
Pathognomonic Features of AIDS
- Oral candidiasis in otherwise healthy adult + unexplained CD4 drop = flag for HIV
- Kaposi's sarcoma in young person = strongly suggests AIDS
- Pneumocystis pneumonia + hypoxia disproportionate to CXR findings
- Cryptococcal meningitis with India ink +ve CSF
3. DIAGNOSIS
Lab Investigations
| Test | Details |
|---|---|
| ELISA (Enzyme Linked Immunosorbent Assay) | Screening test; detects HIV antibodies ± p24 antigen (4th generation = combo); sensitivity ~99.7%; window period issue with older tests |
| Rapid HIV tests | Point-of-care; whole blood/saliva; used in ICTC and PPTCT settings; two different rapid tests required for confirmation in India |
| Western Blot | Confirmatory test (reference standard for antibody detection); detects specific HIV proteins (gp120, gp41, p24, p31) |
| p24 Antigen | Detectable during window period (before antibodies); used in 4th generation combo tests |
| HIV RNA by PCR (Viral Load) | Most sensitive early test; detects viral RNA; used for: diagnosis in infants (<18 months), monitoring ART response, diagnosis during window period. Target: undetectable (<50 copies/mL on treatment) |
| CD4+ T lymphocyte count | Monitors immunological status; determines when to start ART and OI prophylaxis. Normal: 500-1500 cells/µL; AIDS: <200 |
| HIV DNA PCR | Diagnosis in infants (preferred <18 months of age, as maternal antibodies persist) |
| Routine labs | CBC (lymphopaenia, anaemia, thrombocytopaenia); LFT; RFT; HBsAg; VDRL; TB workup; CXR |
India Testing Protocol (NACO):
- Testing Strategy I: Single test for surveillance
- Testing Strategy II: 2 tests (screening + confirmatory) for diagnosis
- Testing Strategy III: 3 tests for diagnosis when seropositivity rate <10%
- All positive results must be confirmed before disclosure; pre- and post-test counselling mandatory
Case Definition (WHO / NACO)
| HIV infected (Adult) | Positive HIV antibody test (confirmed by Western Blot or 2 different rapid tests) |
| AIDS (WHO) | HIV positive + CD4 <200 cells/µL OR presence of any AIDS-defining illness (WHO Stage 3 or 4) |
| AIDS case (CDC) | HIV positive + CD4 <200/µL OR any CDC Category C (AIDS-defining) condition |
| Notifiable? | YES - AIDS is notifiable under IDSP; HIV status is confidential (protected by HIV and AIDS (Prevention and Control) Act, 2017, India) |
4. TREATMENT
General / Supportive Care
- Nutritional support; treat malnutrition
- OI prophylaxis (co-trimoxazole for PCP/toxoplasma when CD4 <200)
- Isoniazid Preventive Therapy (IPT) for TB prevention in PLHIV
- Treat all OIs aggressively
- Psychosocial support; adherence counselling
- Safe sex counselling; partner notification
Specific Treatment - Antiretroviral Therapy (ART)
Goal: Viral suppression (undetectable viral load) → immune reconstitution → prevent OIs, AIDS, death → prevent transmission (U=U: Undetectable = Untransmittable)
When to start ART (WHO/NACO): ALL HIV-positive individuals regardless of CD4 count (Test and Treat strategy, WHO 2015/NACO)
Priority for immediate ART (<2 weeks): AIDS-defining illness, TB co-infection, CD4 <200, pregnant women, HIV-exposed infants, PLHIV with HBV co-infection
First-Line ART Regimens (WHO recommended, 2021):
Adults and Adolescents - Preferred:
| Drug 1 (NRTI) | Drug 2 (NRTI) | Drug 3 (INSTI) |
|---|---|---|
| TDF (Tenofovir) | 3TC (Lamivudine) or FTC | DTG (Dolutegravir) |
TDF + 3TC + DTG = current preferred first-line regimen in India and globally
Alternative first-line: TDF + 3TC + EFV 400 mg
Children (preferred): ABC + 3TC + DTG
Neonates (preferred): AZT + 3TC + RAL
Drug Classes:
| Class | Abbreviation | Examples |
|---|---|---|
| Nucleoside Reverse Transcriptase Inhibitors | NRTI | TDF, AZT, 3TC, ABC, FTC |
| Non-Nucleoside Reverse Transcriptase Inhibitors | NNRTI | EFV (Efavirenz), NVP (Nevirapine) |
| Integrase Strand Transfer Inhibitors | INSTI | DTG (Dolutegravir), RAL (Raltegravir) |
| Protease Inhibitors | PI/r | LPV/r, ATV/r, DRV/r |
Monitoring ART Response:
- Viral Load (most important): target <50 copies/mL by 6-12 months
- CD4 count: should rise >200/µL over time
- Clinical improvement: weight gain, fewer infections
PPTCT (Prevention of Parent-to-Child Transmission):
- Immediate ART for all HIV-positive pregnant women (regardless of CD4) - Option B+
- Infant prophylaxis: NVP (nevirapine) daily for 4-6 weeks after birth
- Safer delivery practices: elective Caesarean section if VL unknown/detectable
- Avoid breastfeeding if safe replacement feeding available; if breastfeeding, continue maternal ART throughout
Post-Exposure Prophylaxis (PEP):
- For healthcare workers after needlestick; or after unprotected sex/sexual assault
- TDF + 3TC + DTG for 28 days
- Must start within 72 hours (ideally <2 hours) of exposure
- Reduces risk of transmission by ~80%
Pre-Exposure Prophylaxis (PrEP):
- TDF + FTC (Emtricitabine) daily for high-risk seronegative individuals
- Reduces HIV acquisition by >90% in MSM; ~75% in heterosexuals
Isolation & Notification
| Isolation type | NO isolation required (WHO: "no public health rationale to justify isolation, quarantine or discrimination based on HIV status"). Standard precautions for healthcare workers |
| Duration of treatment | Lifelong ART |
| Notification | AIDS is notifiable to IDSP. HIV status is confidential under HIV/AIDS (Prevention and Control) Act 2017. Mandatory disclosure only to sexual/injecting partners (by physician, not patient) in limited circumstances |
5. COMPLICATIONS
System-wise Complications
| System | Complication |
|---|---|
| Respiratory | PCP* (CD4 <200); TB (at any CD4); bacterial pneumonia; LIP (lymphoid interstitial pneumonia in children) |
| CNS | Cerebral toxoplasmosis* (CD4 <100); Cryptococcal meningitis*; CMV encephalitis; PML; HIV dementia/encephalopathy; CNS lymphoma |
| GI | Oesophageal candidiasis; Cryptosporidium diarrhoea; CMV colitis; Microsporidiosis; MAC enteritis |
| Ophthalmological | CMV retinitis* (CD4 <50); toxoplasma retinitis; HIV retinopathy |
| Skin | Kaposi's Sarcoma*; Herpes zoster; Molluscum contagiosum; severe seborrhoeic dermatitis |
| Haematological | Anaemia; thrombocytopaenia; lymphopaenia |
| Renal | HIV-associated nephropathy (HIVAN); TDF nephrotoxicity |
| Metabolic | Lipodystrophy; dyslipidaemia; insulin resistance (from ART) |
| Malignancy | Kaposi's Sarcoma; CNS NHL; invasive cervical carcinoma; Burkitt lymphoma |
| Co-infections | TB (leading cause of HIV-related death globally); Hepatitis B/C; syphilis; HPV |
| ART side effects | TDF: nephrotoxicity, bone loss; EFV: neuropsychiatric (vivid dreams, depression); DTG: weight gain; NVP: hepatotoxicity, Steven-Johnson syndrome; AZT: anaemia, lipoatrophy |
* Most dangerous/common fatal OIs - always highlight in exam
6. PREVENTION AND CONTROL (Most Scoring Section)
Primary Prevention - Health Promotion
- Comprehensive sex education; ABC of prevention: Abstinence, Be faithful, Condom use
- Behaviour change communication (BCC) targeting key populations
- Reduce stigma and discrimination; HIV/AIDS Act 2017 protects PLHIV rights
- Needle/syringe exchange programmes for PWID
- Harm reduction strategies
- Health education for truckers, migrants, youth
Primary Prevention - Specific Protection
| Condoms | Male and female condoms - highly effective; free distribution under NACP; 100% Condom Promotion Programme |
| PrEP | TDF + FTC daily for high-risk seronegative individuals; reduces acquisition >90% |
| VMMC | Voluntary Medical Male Circumcision - reduces female-to-male HIV transmission by ~60% (sub-Saharan Africa strategy) |
| PPTCT | ART to all HIV-positive pregnant women (Option B+); infant NVP prophylaxis; safer delivery |
| Blood safety | Screen all donated blood for HIV (ELISA); promote voluntary blood donation; avoid unnecessary transfusions |
| Harm reduction | Needle/syringe programmes (NSP); Opioid Substitution Therapy (OST) with methadone/buprenorphine for PWID |
| Safe injection practices | Use sterile needles; avoid sharing; universal precautions in healthcare |
| Vaccine | NO licensed HIV vaccine currently available |
| Post-Exposure Prophylaxis (PEP) | TDF + 3TC + DTG × 28 days; start within 72 hours |
Secondary Prevention - Early Diagnosis + Prompt Treatment
- ICTC (Integrated Counselling and Testing Centre) - free, voluntary, confidential HIV testing with pre- and post-test counselling; >25,000 ICTCs in India
- Targeted Interventions (TI) - reaching key populations (FSW, MSM, IDU, truckers, migrants) through peer educators and outreach
- PPTCT programme - routine offer of HIV testing to all pregnant women at ANC
- HIV Sentinel Surveillance (HSS) - annual cross-sectional survey of ANC attendees and key populations to monitor HIV trends (unlinked anonymous testing)
- Free ART Centres - nationwide network; >700 ART centres in India
- Test-and-Treat: immediate ART for all diagnosed cases
Tertiary Prevention - Rehabilitation
- Social rehabilitation: anti-discrimination laws (HIV/AIDS Act 2017)
- Support groups for PLHIV (network of positive people - INP+)
- Palliative care for advanced AIDS
- Nutritional rehabilitation
- Management of long-term ART side effects
- Vocational training and community reintegration
Control Measures During an Outbreak
| Step | Action |
|---|---|
| Case identification | Trace sexual/needle-sharing partners; offer testing |
| Intensified TI | Expand targeted interventions in affected area |
| ART scale-up | Ensure universal access to ART |
| Blood safety | Strict screening protocols |
| Health education | Emergency IEC in affected community |
| Notification | NACO → State AIDS Control Society → IDSP |
National Programs & WHO Goals
| NACO | National AIDS Control Organisation - apex body; under Ministry of Health & Family Welfare |
| NACP | National AIDS Control Programme - Phase I (1992), II (1999), III (2007), IV (2012-2017), now integrated into NHM |
| NSP 2017-2024 | National Strategic Plan for HIV/AIDS and STI 2017-2024: Goal = "AIDS Free India" (Zero new infections, Zero AIDS deaths, Zero stigma); Target 95-95-95 (95% know status, 95% on ART, 95% virally suppressed) |
| Key Initiatives | Free ART programme (2004); ICTC; PPTCT; 100% Condom Programme; Targeted Interventions; Opioid Substitution Therapy |
| HIV/AIDS Act | HIV and AIDS (Prevention and Control) Act, 2017 - protects rights of PLHIV; prohibits discrimination |
| WHO/UNAIDS goal | 95-95-95 targets by 2025; End AIDS as public health threat by 2030 (SDG 3.3) |
| U=U | Undetectable = Untransmittable - PLHIV on effective ART with undetectable viral load cannot transmit HIV |
EXAM TIPS TABLE
| Always Mention | Key Facts |
|---|---|
| Incubation period | HIV to AIDS: 8-10 years untreated; window period: 2-12 weeks |
| Period of communicability | Lifelong; highest during acute infection and late AIDS |
| Notifiable | YES (AIDS); HIV is confidential (HIV/AIDS Act 2017) |
| CD4 count in AIDS | <200 cells/µL |
| Gold standard confirmatory | Western Blot (antibody); viral load PCR (early/infant) |
| First-line ART (adults) | TDF + 3TC + DTG (preferred; WHO 2021) |
| When to start ART | ALL HIV-positive persons regardless of CD4 (Test and Treat) |
| Most common OI | PCP (CD4 <200) - most common AIDS-defining OI |
| Most dangerous OI | Cerebral toxoplasmosis / Cryptococcal meningitis (CD4 <100) |
| AIDS-defining malignancy | Kaposi's Sarcoma (HHV-8), CNS NHL |
| PPTCT drug | ART (Option B+) for mother; NVP for infant |
| PEP | TDF + 3TC + DTG × 28 days; within 72 hours |
| PrEP | TDF + FTC daily |
| No vaccine available | Vaccine in development |
| National body | NACO (National AIDS Control Organisation) |
| National programme | NACP (Phase I-IV); now under NHM |
| NSP goal | "AIDS Free India" - Zero new infections, Zero deaths, Zero stigma |
| WHO/UNAIDS goal | 95-95-95 by 2025; End AIDS by 2030 |
| India epidemic type | Concentrated epidemic (not generalised) |
| HIV/AIDS Act | 2017 - anti-discrimination; confidentiality; equal rights |
| TB + HIV | TB = leading cause of HIV-related death globally; co-trimoxazole + IPT for PLHIV |
Exam note: AIDS is a mega-topic in PSM. For 10-mark questions: (1) modes of transmission (all 3 routes) with specific risk percentages, (2) WHO staging with CD4 values, (3) ART first-line regimen (TDF+3TC+DTG), (4) Test-and-Treat (all PLHIV regardless of CD4), (5) PPTCT = Option B+ = ART for all pregnant HIV-positive women. Always end Prevention section with NACP + NSP 2017-2024 goals (Zero new infections, Zero deaths, Zero stigma) + 95-95-95 targets. Mention HIV/AIDS Act 2017 for full marks.
Just name the next disease!
Leptospirosis
Your credits are exhausted. You can purchase a top-up or subscribe to a plan to continue using Orris. If you're already subscribed, your daily credits will reset tomorrow.
This is a shared conversation. Sign in to Orris to start your own chat.